

ANNEX 1

ANNEX 2

ANNEX 3

ANNEX 4

ANNEX 5

ANNEX 6

ANNEX 7

Table 1

Table 2

Table 3

Table 4

Table 5

Table 6

Table 7

Table 8

Call Evaluation Report

HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage, HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage

HORIZON-JU-GH-EDCTP3-2025-04-two-stage

HORIZON-JU-GH-EDCTP3-2025-04-two-stage

9-3-25 17:00 a

Call ranked list(s)

List of below threshold proposals

List of inadmissible proposals

List of ineligible proposals

Evaluation statistics, number of proposals, number of participants and EU requested contribution in evaluated, retained for funding and reserve list proposals

Track list of evaluated proposals

Call specific statistics

Geographic origin and gender of independent experts

Affiliation of independent experts

Gender of coordinators and applicants' person in charge in evaluated and in retained for funding proposals

Applicants' activity type in evaluated and in retained for funding proposals

SME participation in evaluated and in retained for funding proposals

SME coordinators in evaluated and retained for funding proposals

List of participants in evaluated proposals

Country participation and share of requested EU contribution in evaluated and retained for funding proposals

Status	EU Rank	Criteria to determine ranking in case of equal score (only applicable around funding threshold)	Overall score	Overall score, weighted and normalised to 15	Topic	Panel	Step
Main list	1		15,00	15,00	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Main list	2		15,00	15,00	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Main list	3		14,50	14,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Main list	4		14,50	14,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Main list	5		14,50	14,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Main list	6		14,50	14,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Main list	7		14,50	14,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Below available budget	8		14,00	14,00	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Below available budget	9		14,00	14,00	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Below available budget	10		13,50	13,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Below available budget	11		13,50	13,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Below available budget	12		13,50	13,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1

Below available budget	13		13,00	13,00	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Below available budget	14		13,00	13,00	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Below available budget	15		12,50	12,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Below available budget	16		12,50	12,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Below available budget	17		12,00	12,00	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	1
Main list	1		14,50	14,50	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	1
Main list	2		13,00	13,00	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	1
Main list	3		12,50	12,50	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	1
Main list	4		12,00	12,00	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	1

ANNEX 1: Call ranked list(s)

Type of Action	Proposal Number	Acronym	Title
HORIZON-JU-RIA	101249120	TEST4TPT	AI assisted innovative low-cost skin testing model to accelerate person-centered TB prevention services in Tanzania, Mozambique and Uganda.
HORIZON-JU-RIA	101248882	ASQA-PAC	Advancing child-friendly artesunate-amodiaquine taste mask coated micro pellets to combat the threat of artemisinin resistant malaria in Africa
HORIZON-JU-RIA	101248942	R2D2-xDRTB	Rapid Research in Next-Generation Diagnostics Development for Drug-Resistant Tuberculosis
HORIZON-JU-RIA	101249004	RECENT-TB	Recurrent TB Screening and Prevention Study
HORIZON-JU-RIA	101248855	AddiCAD	FIELD TESTING OF ADDICAD: AN INNOVATIVE DIAGNOSTIC TEST FOR TUBERCULOSIS THAT ADDS TO CAD
HORIZON-JU-RIA	101249059	SWAB -IMPACT	SWAB-IMPACT: Swab-Based Molecular Testing for Impact on TB Diagnosis and Treatment
HORIZON-JU-RIA	101248845	PRECISE-TBM	Prospective evaluation and refinement of novel biomarker-based point-of-care tests for the diagnosis of tuberculous meningitis in children
HORIZON-JU-RIA	101248850	PATHFINDER	Point-of-care Lab-on-Chip Detection of Host Response in Febrile Illness for Diagnosis and Etiology Research
HORIZON-JU-RIA	101248873	ACT4KIDS-TB	Actiphage-supported Clinical Tools for Knowledge-driven Innovations in Diagnostic Solutions for TB in young children
HORIZON-JU-RIA	101248978	ACT-Africa	Using Artificial Intelligence to Develop Affordable and Efficient Clinical Data Management Systems to Accelerate Quality Clinical Research Output from Africa
HORIZON-JU-RIA	101249082	M-Pact	ENHANCING EQUITABLE VACCINE ACCESS THROUGH REDUCED-DOSE MPOX VACCINATION USING VAX-ID IN SUB-SAHARAN AFRICA
HORIZON-JU-RIA	101248923	ParasiteAID	PARAsitic diseases of sub-Saharan africa early deTection, IDentification and management with Artificial Intelligence (ParasiteAID)

HORIZON-JU-RIA	101248841	MRI of the Tyger	AFFORDABLE NEUROIMAGING FOR DIAGNOSIS AND MONITORING OF INFECTIOUS DISEASES IN SUB-SAHARAN AFRICA
HORIZON-JU-RIA	101248953	FRONTLINE	Field Evaluation and Randomised Controlled Trial of a Dried Spot Kit for Improved Diagnosis and Surveillance of AMR Bacterial Infections in Malawi, and Ghana
HORIZON-JU-RIA	101249036	InfectoTest	FIRST HIGHLY SENSITIVE MALARIA DIAGNOSTICS FOR ASYMPTOMATIC LOW-DENSITY INFECTIONS AT POINT-OF-CARE (INFECTOTEST)
HORIZON-JU-RIA	101248865	TB-DISCOVER	Tuberculosis Diagnostics using Innovative Swab and CAD for Optimized Validation and Enhanced Response for children
HORIZON-JU-RIA	101248837	SERMAVAL	SEASONAL MASS VACCINATION WITH MASS DRUG ADMINISTRATION FOR MALARIA ELIMINATION
HORIZON-JU-RIA	101249026	TARGET	TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea and malnutrition
HORIZON-JU-RIA	101248844	HUNADIA	Next-gen cholera treatment for faster recovery, lower mortality and better outbreak control
HORIZON-JU-RIA	101248902	CARE-Africa	Novel Interventions to Identify and Control Diarrhoeal Diseases in Sub-Saharan Africa
HORIZON-JU-RIA	101248988	PRoRota	SAFETY, EFFECTIVENESS AND COST-EFFECTIVENESS OF PROBIOTICS AS ADJUNCT PREVENTIVE THERAPY FOR CHILDHOOD DIARRHOEA AND ANTIMICROBIAL RESISTANCE IN AFRICA: A DOUBLE-BLINDED

Coordinating organisation	Country coordinator	Duration (months)	Total Cost	Requested EU contribution	Recommended EU Contribution	Cumulative EU Contribution
KONINKLIJKE NEDERLANDSE CENTRALE VERENIGING	NL	36	2.248.981,25 €	2.248.981,25 €	2.248.981,25 €	2.248.981,25 €
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF	UK	36	2.099.745,75 €	2.099.745,75 €	2.099.745,75 €	4.348.727,00 €
UNIVERSITÄTSKLINIKUM HEIDELBERG	DE	36	2.099.625,50 €	2.099.625,50 €	2.099.625,50 €	6.448.352,50 €
STICHTING AMSTERDAM UMC	NL	48	2.394.773,75 €	2.394.773,75 €	2.394.773,75 €	8.843.126,25 €
STELLENBOSCH UNIVERSITY	ZA	36	2.564.405,25 €	2.176.905,25 €	2.176.905,25 €	11.020.031,50 €
THE AURUM INSTITUTE NPC	ZA	36	2.369.338,75 €	2.352.258,75 €	2.352.258,75 €	13.372.290,25 €
STELLENBOSCH UNIVERSITY	ZA	48	2.158.288,75 €	2.158.288,75 €	2.158.288,75 €	15.530.579,00 €
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE	UK	42	2.753.913,75 €	2.753.913,75 €	2.753.913,75 €	18.284.492,75 €
INSTITUUT VOOR TROPISCHE GENEESKUNDE	BE	48	2.059.163,75 €	2.059.163,75 €	2.059.163,75 €	20.343.656,50 €
WITS HEALTH CONSORTIUM (PTY) LTD	ZA	50	2.000.000,00 €	2.000.000,00 €	2.000.000,00 €	22.343.656,50 €
UNIVERSITEIT ANTWERPEN	BE	36	2.287.992,50 €	2.287.992,50 €	2.287.992,50 €	24.631.649,00 €
UNIVERSIDAD POLITECNICA DE MADRID	ES	48	2.089.091,25 €	2.089.091,25 €	2.089.091,25 €	26.720.740,25 €

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES	ES	36	2.499.336,25 €	2.499.336,25 €	2.499.336,25 €	29.220.076,50 €
LIVERPOOL SCHOOL OF TROPICAL MEDICINE	UK	36	2.299.999,25 €	2.299.999,25 €	2.299.999,25 €	31.520.075,75 €
Zendia GmbH	DE	36	2.329.905,50 €	2.329.905,50 €	2.329.905,50 €	33.849.981,25 €
WORLD ALLIANCE FOR LUNG AND INTENSIVE CARE MEDICINE IN	UG	36	2.060.923,75 €	2.060.923,00 €	2.060.923,00 €	35.910.904,25 €
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL	UK	30	2.297.500,00 €	2.297.500,00 €	2.297.500,00 €	38.208.404,25 €
STICHTING AMSTERDAM UMC	NL	54	5.799.966,25 €	5.799.966,25 €	5.799.966,25 €	5.799.966,25 €
Hunazine Biotech SL	ES	48	5.628.262,50 €	5.628.262,50 €	5.628.262,50 €	11.428.228,75 €
THE UNIVERSITY OF NOTTINGHAM	UK	36	4.808.785,75 €	4.808.785,75 €	4.808.785,75 €	16.237.014,50 €
UNIVERSITETET I BERGEN	NO	48	5.834.001,25 €	5.300.000,00 €	5.300.000,00 €	21.537.014,50 €

Overall score	Topic	Panel	Type of Action	Proposal number	Acronym
11,50	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101249017	ECOLI-CEA
11,50	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101249128	OptiCryptO
11,50	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101248926	BRACED
11,50	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101248922	DIASMART
11,00	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101248890	SAFE-GUT
7,50	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101249050	SHIELD Africa
12,00	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249056	TB MetNac
11,00	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249123	R-RDT4TB
10,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248985	eHEALNTD
10,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248939	C2K-ACCESS
10,00	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249009	INASMAL
10,00	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248987	AzithroTAB
9,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249071	TACTIC
8,50	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248848	BCG-SSA
6,00	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249113	LIFE3

NNEX 2: List(s) of below-threshold proposals

Title	Coordinating organisation	Country coordinator	Duration (months)	Total Cost
Tackling and investigating Escherichia coli Induced Diarrheal Diseases in Central and East Africa (ECOLI-CEA)	R-EVOLUTION WORLDWIDE SRL - IMPRESA SOCIALE	IT	48	5.530.945,00 €
OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children aged 1-2 years in Nigeria and Chad	UNIVERSITE DE BORDEAUX	FR	36	5.587.723,75 €
Bran for Resilience Against Childhood Enteric and Diarrhoeal disease and Environmental challenges	THE UNIVERSITY OF BIRMINGHAM	UK	48	5.299.375,25 €
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	FONDAZIONE PER LA RICERCA FARMACOLOGICA GIANNI BENZI ONLUS	IT	60	5.299.998,75 €
Sustainable Approaches for Food-based Enhancement of Gut Health to tackle Childhood Diarrhoeal Diseases in the Context of Climate Change	STICHTING VU	NL	60	5.299.952,00 €
Integrated Public Health and Climate Resilience Strategies for Tackling Antibiotic-Resistant Shigella and Reducing Diarrhea in Sub-Saharan Africa	RHODES UNIVERSITY	ZA	48	5.278.780,00 €
PIONEERING ADJUVANT IMMUNOTHERAPY TO PROMOTE LUNG FUNCTION RECOVERY AMONG PATIENTS WITH DRUG SUSCEPTIBLE TUBERCULOSIS IN HIGH BURDEN COUNTRIES	EUROPEAN VACCINE INITIATIVE E.V	DE	36	2.311.060,00 €
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	THE UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS	UK	48	2.360.865,00 €
Leveraging eHealth to Overcome Barriers in NTDs: Enhancing Access to Anthelmintic Treatment for Schistosomiasis and Soil-transmitted Helminths	INSTITUTO DE SALUD CARLOS III	ES	48	2.705.060,00 €
Accelerating Capillary blood Self-Collection using the C2K device for Expanded Screening, and Surveillance of Infectious Diseases in Sub-Saharan Africa	INSTITUUT VOOR TROPISCHE GENEESKUNDE	BE	48	2.740.830,00 €
MULTICENTRE, INTERVENTIONAL, OPEN-LABEL PHASE 2/3 STUDY OF THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS OF INTRANASAL ARTESUNATE IN	EUNOVIS	FR	48	2.883.533,75 €
Evaluating pharmacokinetics, acceptability and tolerability of novel azithromycin orally disintegrating mini tablets in comparison to standard suspension and defining a roadmap towards access	CITY ST GEORGES UNIVERSITY OF LONDON	UK	42	2.414.426,50 €
TRANSFORMING ADVANCED HIV CARE WITH A TARGETED INTERVENTION FOR CMV (TACTIC): A Phase 3 Randomised Controlled Trial	LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER	UK	48	2.476.826,25 €
Does BCG vaccine reduce mortality among seniors over 50 years of age in two countries in Sub-Saharan Africa? Two randomised controlled trials (BCG-SeniorS-Africa)	SYDDANSK UNIVERSITET	DK	60	2.100.000,00 €
Forging Innovative and Lasting Pathways for the Elimination of Paediatric HIV through Prevention, Early Testing, and Treatment	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN	DE	60	7.209.620,00 €

Requested EU contribution	Justification
5.530.942,00 €	Below Threshold
5.587.723,75 €	Below Threshold
5.299.375,25 €	Below Threshold
5.299.998,75 €	Below Threshold
5.299.952,00 €	Below Threshold
5.278.780,00 €	Below Threshold
2.300.435,00 €	Below Threshold
2.360.865,00 €	Below Threshold
2.705.060,00 €	Below Threshold
2.740.830,00 €	Below Threshold
2.814.934,75 €	Below Threshold
2.414.426,50 €	Below Threshold
2.300.000,00 €	Below Threshold
2.100.000,00 €	Below Threshold
7.209.620,00 €	Below Threshold

Topic	Panel	Type of Action	Proposal number	Acronym
-------	-------	----------------	-----------------	---------

inadmissible proposals

Title	Duration (months)	Total Cost	Requested EU contribution	Reason(s) for non- admissibility
-------	----------------------	------------	------------------------------	-------------------------------------

Topic	Panel	Type of Action	Proposal number	Acronym
-------	-------	----------------	-----------------	---------

X 4: List of ineligible proposals

Title	Duration (months)	Total Cost	Requested EU contribution
-------	----------------------	------------	---------------------------

Reason(s) for ineligibility

ANNEX 5: Evaluation statistics, number of proposals, number of participant

Topic	Panel	Type of Action	Number of proposals evaluated	Number of proposals retained for funding	Success Rate	Number of proposals in reserve list
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	26	7	26,92 %	0
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	10	4	40,00 %	0
TOTAL			36	11	30,56 %	0

its and EU requested contribution in evaluated, retained for funding and reserve list proposals

Number of participants in evaluated proposals	Number of participants in retained for funding proposals	Success Rate	Number of participants in proposals in reserve list	Requested EU contribution in evaluated proposals	Requested EU contribution in retained for funding proposals	Recommended EU contribution in retained for funding proposals	Success Rate	Requested EU contribution in proposals in reserve list
167	37	22,16 %	0	65.154.575,50 €	15.530.579,00 €	15.530.579,00 €	23,84 %	0,00 €
91	33	36,26 %	0	53.833.786,25 €	21.537.014,50 €	21.537.014,50 €	40,01 %	0,00 €
258	70	27,13 %	0	118.988.361,75 €	37.067.593,50 €	37.067.593,50 €	31,15 %	0,00 €

**Recommended EU
contribution in
proposals in
reserve list**

Topic	Panel	Type of Action	Proposal number	Acronym
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248978	ACT-Africa
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248873	ACT4KIDS-TB
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248882	ASAQ-PAC
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248855	AddiCAD
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248987	AzithroTAB
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248848	BCG-SSA
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101248926	BRACED
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248939	C2K-ACCESS
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101248902	CARE-Africa
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101248922	DIASmart
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101249017	ECOLI-CEA
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248953	FRONTLINE
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101248844	HUNADIA
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249009	INASMAL
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249036	InfectoTest
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249113	LIFE3
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249082	M-Pact
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248841	MRI of the Tyger
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101249128	OptiCryptO
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248850	PATHFINDER
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248845	PRECISE-TBM
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101248988	PRoRota
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248923	ParasiteAID
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249123	R-RDT4TB
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248942	R2D2-xDRTB

HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249004	RECENT-TB
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101248890	SAFE-GUT
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248837	SERMAVAL
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101249050	SHIELD Africa
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249059	SWAB -IMPACT
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249071	TACTIC
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101249026	TARGET
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249056	TB MetNac
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248865	TB-DISCOVER
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101249120	TEST4TPT
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248985	eHEALNTD

ANNEX 6: Track list of evaluated proposals

Title	Duration (months)	Coordinating organisation	Country coordinator	Number of participants	Total eligible costs
Using Artificial Intelligence to Develop Affordable and Efficient Clinical Data Management Systems to Accelerate Quality Clinical Research Output from Actiphage-supported Clinical Tools for Knowledge-driven Innovations in Diagnostic Solutions for TB in young children	50	WITS HEALTH CONSORTIUM	ZA	8	2.000.000,00 €
Advancing child-friendly artesunate-amodiaquine taste mask coated micro pellets to combat the threat of artemisinin resistant malaria in Africa	48	INSTITUUT VOOR TROPISCHE	BE	6	2.059.163,75 €
FIELD TESTING OF ADDICAD: AN INNOVATIVE DIAGNOSTIC TEST FOR TUBERCULOSIS THAT ADDS TO CAD	36	THE CHANCELLOR STELLENBOSCH UNIVERSITY	UK	5	2.099.745,75 €
Evaluating pharmacokinetics, acceptability and tolerability of novel azithromycin orally disintegrating mini tablets in comparison to standard suspension and Does BCG vaccine reduce mortality among seniors over 50 years of age in two countries in Sub-Saharan Africa? Two randomised controlled trials (BCG-Bran for Resilience Against Childhood Enteric and Diarrhoeal disease and Environmental challenges	36	CITY ST GEORGES	ZA	6	2.564.405,25 €
Accelerating Capillary blood Self-Collection using the C2K device for Expanded Screening and Surveillance of Infectious Diseases in Sub-Saharan Africa	42	SYDDANSK UNIVERSITET	UK	8	2.414.426,50 €
Novel Interventions to Identify and Control Diarrhoeal Diseases in Sub-Saharan Africa	60	THE UNIVERSITY OF BIRMINGHAM	DK	3	2.100.000,00 €
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	48	INSTITUUT VOOR TROPISCHE	UK	7	5.299.375,25 €
Tackling and investigating Escherichia coli Induced Diarrheal Diseases in Central and East Africa (ECOLI-CEA)	48	THE UNIVERSITY OF NOTTINGHAM	BE	6	2.740.830,00 €
Field Evaluation and Randomised Controlled Trial of a Dried Spot Kit for Improved Diagnosis and Surveillance of AMR Bacterial Infections in Malawi and Next-gen cholera treatment for faster recovery, lower mortality and better outbreak control	36	FONDAZIONE PER LA RICERCA	UK	6	4.808.785,75 €
MULTICENTRE, INTERVENTIONAL, OPEN-LABEL PHASE 2/3 STUDY OF THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS OF FIRST HIGHLY SENSITIVE MALARIA DIAGNOSTICS FOR ASYMPTOMATIC LOW-DENSITY INFECTIONS AT POINT-OF-CARE (INFECTOTEST)	48	R-EVOLUTION WORLDWIDE SRI	IT	14	5.299.998,75 €
Forging Innovative and Lasting Pathways for the Elimination of Paediatric HIV through Prevention, Early Testing, and Treatment	36	LIVERPOOL SCHOOL OF	IT	9	5.530.945,00 €
ENHANCING EQUITABLE VACCINE ACCESS THROUGH REDUCED-DOSE MPOX VACCINATION USING VAX-ID IN SUB-SAHARAN AFRICA	48	Hunazine Biotech SI	UK	8	2.299.999,25 €
AFFORDABLE NEUROIMAGING FOR DIAGNOSIS AND MONITORING OF INFECTIOUS	48	EUNOVIS	ES	11	5.628.262,50 €
OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children	36	Zendia GmbH	FR	6	2.883.533,75 €
Point-of-care Lab-on-Chip Detection of Host Response in Febrile Illness for Diagnosis and Etiology Research	60	LUDWIG-MAXIMILIANS-UNIVERSITÄT WÜRZBURG	DE	6	2.329.905,50 €
Prospective evaluation and refinement of novel biomarker-based point-of-care tests for the diagnosis of tuberculous meningitis in children	36	UNIVERSITEIT ANTWERPEN	DE	10	7.209.620,00 €
SAFETY, EFFECTIVENESS AND COST-EFFECTIVENESS OF PROBIOTICS AS ADJUNCT PREVENTIVE THERAPY FOR CHILDHOOD DIARRHOEA AND PARASITIC diseases of sub-Saharan Africa early detection, Identification and management with Artificial Intelligence (ParasiteAID)	36	AGENCIA ESTATAL	BE	6	2.287.992,50 €
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	36	UNIVERSITE DE BORDEAUX	ES	6	2.499.336,25 €
Rapid Research in Next-Generation Diagnostics Development for Drug-Resistant Tuberculosis	42	IMPERIAL COLLEGE OF	FR	6	5.587.723,75 €
	48	STELLENBOSCH UNIVERSITY	UK	6	2.753.913,75 €
	48	UNIVERSITETET I BERGEN	ZA	6	2.158.288,75 €
	48	UNIVERSIDAD POLITECNICA DE	NO	6	5.834.001,25 €
	48	THE UNIVERSITY COURT OF THE UNIVERSITÄTSKLINIKUM	ES	13	2.089.091,25 €
	48	THE UNIVERSITY	UK	13	2.360.865,00 €
	36	UNIVERSITÄTSKLINIKUM	DE	4	2.099.625,50 €

Recurrent TB Screening and Prevention Study	48	STICHTING AMSTERDAM	NL	5	2.394.773,75 €
Sustainable Approaches for Food-based Enhancement of Gut Health to tackle <u>Childhood Diarrhoeal Diseases in the Context of Climate Change</u>	60	STICHTING VU	NL	8	5.299.952,00 €
SEASONAL MASS VACCINATION WITH MASS DRUG ADMINISTRATION FOR MALARIA ELIMINATION	30	LONDON SCHOOL OF HYGIENE AND	UK	5	2.297.500,00 €
Integrated Public Health and Climate Resilience Strategies for Tackling <u>Antibiotic-Resistant Shigella and Reducing Diarrhea in Sub-Sahara Africa</u>	48	RHODES UNIVERSITY	ZA	8	5.278.780,00 €
SWAB-IMPACT: Swab-Based Molecular Testing for Impact on TB Diagnosis <u>and Treatment</u>	36	THE AURUM INSTITUTE NPC	ZA	3	2.369.338,75 €
TRANSFORMING ADVANCED HIV CARE WITH A TARGETED INTERVENTION FOR CMV (TACTIC): A Phase 3 Randomised Controlled Trial	48	LONDON SCHOOL OF HYGIENE AND	UK	3	2.476.826,25 €
TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea <u>and malnutrition</u>	54	STICHTING AMSTERDAM	NL	10	5.799.966,25 €
PIONEERING ADJUVANT IMMUNOTHERAPY TO PROMOTE LUNG FUNCTION RECOVERY AMONG PATIENTS WITH DRUG SUSCEPTIBLE-	36	EUROPEAN VACCINE	DE	5	2.311.060,00 €
Tuberculosis Diagnostics using Innovative Swab and CAD for Optimized <u>Validation and Enhanced Response for children</u>	36	WORLD ALLIANCE FOR LUNG AND	UG	3	2.060.923,75 €
AI assisted innovative low-cost skin testing model to accelerate person-centered <u>TB prevention services in Tanzania, Mozambique and Uganda</u>	36	KONINKLIJKE NEDERLANDSE	NL	8	2.248.981,25 €
Leveraging eHealth to Overcome Barriers in NTDs: Enhancing Access to <u>Anthelmintic Treatment for Schistosomiasis and Soil-transmitted Helminths</u>	48	INSTITUTO DE SALUD CARLOS III	ES	9	2.705.060,00 €

Requested EU contribution	Recommended EU contribution	Final Score	Panel Rank	EU Rank	Status
2.000.000,00 €		13,50	10	10	Below available budget
2.059.163,75 €		14,00	9	9	Below available budget
2.099.745,75 €	2.099.745,75 €	15,00	2	2	Main list
2.176.905,25 €	2.176.905,25 €	14,50	5	5	Main list
2.414.426,50 €		10,00	23	23	Below Threshold
2.100.000,00 €		8,50	25	25	Below Threshold
5.299.375,25 €		11,50	7	7	Below Threshold
2.740.830,00 €		10,50	21	21	Below Threshold
4.808.785,75 €	4.808.785,75 €	12,50	3	3	Main list
5.299.998,75 €		11,50	8	8	Below Threshold
5.530.942,00 €		11,50	5	5	Below Threshold
2.299.999,25 €		13,00	14	14	Below available budget
5.628.262,50 €	5.628.262,50 €	13,00	2	2	Main list
2.814.934,75 €		10,00	22	22	Below Threshold
2.329.905,50 €		12,50	15	15	Below available budget
7.209.620,00 €		6,00	26	26	Below Threshold
2.287.992,50 €		13,50	11	11	Below available budget
2.499.336,25 €		13,00	13	13	Below available budget
5.587.723,75 €		11,50	6	6	Below Threshold
2.753.913,75 €		14,00	8	8	Below available budget
2.158.288,75 €	2.158.288,75 €	14,50	7	7	Main list
5.300.000,00 €	5.300.000,00 €	12,00	4	4	Main list
2.089.091,25 €		13,50	12	12	Below available budget
2.360.865,00 €		11,00	19	19	Below Threshold
2.099.625,50 €	2.099.625,50 €	14,50	3	3	Main list

2.394.773,75 €	2.394.773,75 €	14,50	4	4	Main list
5.299.952,00 €		11,00	9	9	Below Threshold
2.297.500,00 €		12,00	17	17	Below available budget
5.278.780,00 €		7,50	10	10	Below Threshold
2.352.258,75 €	2.352.258,75 €	14,50	6	6	Main list
2.300.000,00 €		9,50	24	24	Below Threshold
5.799.966,25 €	5.799.966,25 €	14,50	1	1	Main list
2.300.435,00 €		12,00	18	18	Below Threshold
2.060.923,00 €		12,50	16	16	Below available budget
2.248.981,25 €	2.248.981,25 €	15,00	1	1	Main list
2.705.060,00 €		10,50	20	20	Below Threshold

ANNEX 7 Table 1: Geographic origin and gender of independent experts

Country group	Country	Number of female experts	%	Number of male experts	%	Total
Associated Countries	Serbia	2	100,00 %	0	0,00 %	2
Associated Countries	United Kingdom	0	0,00 %	1	100,00 %	1
Associated Countries		2	66,67 %	1	33,33 %	3
EU Member States	Croatia	0	0,00 %	1	100,00 %	1
EU Member States	Estonia	0	0,00 %	1	100,00 %	1
EU Member States	Finland	1	50,00 %	1	50,00 %	2
EU Member States	France	0	0,00 %	1	100,00 %	1
EU Member States	Germany	1	50,00 %	1	50,00 %	2
EU Member States	Greece	0	0,00 %	1	100,00 %	1
EU Member States	Italy	2	66,67 %	1	33,33 %	3
EU Member States	Latvia	0	0,00 %	1	100,00 %	1
EU Member States	Portugal	2	66,67 %	1	33,33 %	3
EU Member States	Spain	2	50,00 %	2	50,00 %	4
EU Member States		8	42,11 %	11	57,89 %	19
Third countries	Botswana	1	100,00 %	0	0,00 %	1
Third countries	Cameroon	0	0,00 %	1	100,00 %	1
Third countries	Canada	1	100,00 %	0	0,00 %	1

Third countries	Eswatini	1	100,00 %	0	0,00 %	1
Third countries	Ethiopia	0	0,00 %	1	33,33 %	3
Third countries	Ghana	1	50,00 %	1	50,00 %	2
Third countries	Kenya	1	100,00 %	0	0,00 %	1
Third countries	Mozambique	0	0,00 %	1	100,00 %	1
Third countries	Nigeria	2	50,00 %	1	25,00 %	4
Third countries	South Africa	3	75,00 %	0	0,00 %	4
Third countries	Sudan	0	0,00 %	1	50,00 %	2
Third countries	Uganda	0	0,00 %	1	100,00 %	1
Third countries	United States	0	0,00 %	1	100,00 %	1
Third countries	Zambia	0	0,00 %	1	100,00 %	1
Third countries	Zimbabwe	1	50,00 %	1	50,00 %	2
Third countries		11	42,31 %	10	38,46 %	26
GRAND TOTAL		21	43,75 %	22	45,83 %	48

ANNEX 7 Table 2: Affiliation of independent experts

Country group	Organisation Country	Number of experts from Higher education	%	Number of experts from Research organisations	%	Number of experts from Non-research public bodies	%
		5	35,71 %	3	21,43 %	5	35,71 %
		5	35,71 %	3	21,43 %	5	35,71 %
Third countries	AU	1	100,00 %	0	0,00 %	0	0,00 %
Third countries	BW	1	100,00 %	0	0,00 %	0	0,00 %
Third countries	ET	0	0,00 %	1	100,00 %	0	0,00 %
Third countries	GH	0	0,00 %	1	100,00 %	0	0,00 %
Third countries	MZ	0	0,00 %	0	0,00 %	0	0,00 %
Third countries	NG	1	100,00 %	0	0,00 %	0	0,00 %
Third countries	SD	1	100,00 %	0	0,00 %	0	0,00 %
Third countries	SZ	0	0,00 %	1	100,00 %	0	0,00 %
Third countries	UG	1	100,00 %	0	0,00 %	0	0,00 %
Third countries	US	1	100,00 %	0	0,00 %	0	0,00 %
Third countries	ZA	2	66,67 %	0	0,00 %	0	0,00 %
Third countries		8	61,54 %	3	23,08 %	0	0,00 %
EU Member States	DE	1	50,00 %	0	0,00 %	0	0,00 %
EU Member States	EE	1	100,00 %	0	0,00 %	0	0,00 %
EU Member States	ES	1	33,33 %	1	33,33 %	1	33,33 %

EU Member States	FI	0	0,00 %	0	0,00 %	0	0,00 %
EU Member States	FR	0	0,00 %	0	0,00 %	0	0,00 %
EU Member States	HR	1	100,00 %	0	0,00 %	0	0,00 %
EU Member States	IT	0	0,00 %	1	50,00 %	1	50,00 %
EU Member States	LV	0	0,00 %	0	0,00 %	1	100,00 %
EU Member States	PT	1	50,00 %	0	0,00 %	0	0,00 %
EU Member States		5	35,71 %	2	14,29 %	3	21,43 %
Associated Countries	RS	0	0,00 %	2	100,00 %	0	0,00 %
Associated Countries	UK	2	40,00 %	2	40,00 %	0	0,00 %
Associated Countries		2	28,57 %	4	57,14 %	0	0,00 %
GRAND TOTAL		20	41,67 %	12	25,00 %	8	16,67 %

Number of experts from Non-research private bodies	%	Number of experts from Other type of organisation	%	Total
0	0,00 %	1	7,14 %	14
0	0,00 %	1	7,14 %	14
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	1
1	100,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	1
1	33,33 %	0	0,00 %	3
2	15,38 %	0	0,00 %	13
0	0,00 %	1	50,00 %	2
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	3

0	0,00 %	1	100,00 %	1
1	100,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	1
0	0,00 %	0	0,00 %	2
0	0,00 %	0	0,00 %	1
0	0,00 %	1	50,00 %	2
1	7,14 %	3	21,43 %	14
0	0,00 %	0	0,00 %	2
0	0,00 %	1	20,00 %	5
0	0,00 %	1	14,29 %	7
3	6,25 %	5	10,42 %	48

**ANNEX 7 Table 3: Gender of coordinators and applicants' person in charge in evaluated and in the retained for funding p
only for MSCA-IE)**

	Number of coordinators in evaluated proposals	Number of coordinators in retained proposals	Success rate	Number of participants in evaluated proposals	Number of participants in retained proposals	Success rate
Female	13	7	53,85 %	82	28	34,15 %
Male	23	4	17,39 %	157	36	22,93 %
No gender information	0	0	0,00 %	1	0	0,00 %
TOTAL	36	11	30,56 %	240	64	26,67 %

roposals (including gender or researchers

Topic	Panel	Type of Action	Number of participants from Higher or secondary education in evaluated proposals	% (out of total participants)	Number of participants from Higher or secondary education in retained for funding proposals	% (out of total participants in retained proposals)
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	Research and Innovation Actions	38	35,51 %	10	38,46 %
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	Research and Innovation Actions	69	64,49 %	16	61,54 %
TOTAL			107	100,00 %	26	100,00 %

ANNEX 7 Table 4: Applicants' activity type in evaluated and in retained for funding proposals

Success rate	Number of participants from Research organisations in evaluated proposals	% (out of total participants)	Number of participants from Research organisations in retained for funding proposals	% (out of total participants in retained proposals)	Success rate	Number of participants from Private for profit organisations (excl. education) in evaluated proposals	% (out of total participants)	Number of participants from Private for profit organisations (excl. education) in retained for funding proposals	% (out of total participants in retained proposals)	Success rate
26,32 %	29	36,71 %	11	55,00 %	37,93 %	10	23,26 %	5	33,33 %	50,00 %
23,19 %	50	63,29 %	9	45,00 %	18,00 %	33	76,74 %	10	66,67 %	30,30 %
24,30 %	79	100,00 %	20	100,00 %	25,32 %	43	100,00 %	15	100,00 %	34,88 %

Number of participants from Public body (excl. research and education) in evaluated proposals	% (out of total participants)	Number of participants from Public body (excl. research and education) in retained for funding proposals	% (out of total participants in retained proposals)	Success rate	Number of participants from Other type of organisation in evaluated proposals	% (out of total participants)	Number of participants from Other type of organisation in retained for funding proposals	% (out of total participants in retained proposals)	Success rate
2	28,57 %	2	100,00 %	100,00 %	12	54,55 %	5	71,43 %	41,67 %
5	71,43 %	0	0,00 %	0,00 %	10	45,45 %	2	28,57 %	20,00 %
7	100,00 %	2	100,00 %	28,57 %	22	100,00 %	7	100,00 %	31,82 %

Total number of participants in evaluated proposals	Total number of participants in retained for funding proposals	Success rate
91	33	36,26 %
167	37	22,16 %
258	70	27,13 %

ANNEX 7 Table 5: SME pa

Topic	Panel	Type of Action	Total number of participants in evaluated proposals	Total requested EU contribution of evaluated proposals	Number of SMEs in evaluated proposals	% (of SMEs in evaluated proposals)
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	Research and Innovation Actions	167	65.154.575,50 €	25	14,97 %
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	Research and Innovation Actions	91	53.833.786,25 €	7	7,69 %
TOTAL			258	118.988.361,75 €	32	12,40 %

Participation in evaluated and in retained for funding proposals

Total requested EU contribution of SMEs in evaluated proposals	% (share of SMEs requested EU contribution in evaluated proposals)	Total number of participants in retained for funding proposals	Total requested EU contribution of retained for funding proposals	Number of SMEs in retained for funding proposals	% (of SMEs in retained for funding proposals)	Total requested EU contribution of SMEs in retained for funding proposals	% (share of SMEs requested EU contribution in retained for funding proposals)	Success rate of total participants	Success rate of Requested EU contribution
9.157.364,50 €	14,05 %	37	15.530.579,00 €	9	24,32 %	3.234.369,50 €	20,83 %	22,16 %	100,00 %
5.286.135,00 €	9,82 %	33	21.537.014,50 €	5	15,15 %	4.809.276,25 €	22,33 %	36,26 %	100,00 %
14.443.499,50 €	12,14 %	70	37.067.593,50 €	14	20,00 %	8.043.645,75 €	21,70 %	27,13 %	100,00 %

Success rate of SMEs participants	%
36,00 %	
71,43 %	
43,75 %	

ANNEX 7 Table 6: SME coordinators in evaluated and retained for funding propos

Topic	Panel	Type of Action	Total coordinators in evaluated proposals	Total SME coordinators in evaluated proposals	% SME coordinators in evaluated proposals	Total coordinators in retained for funding proposals
HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	Research and Innovation Actions	10	1	10,00 %	4
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	Research and Innovation Actions	26	2	7,69 %	7
TOTAL			36	3	8,33 %	11

als

Total SME coordinators in retained for funding proposals	% SME coordinators in retained for funding proposals	Success rate coordinators	Success rate SME coordinators
1	25,00 %	40,00 %	100,00 %
0	0,00 %	26,92 %	0,00 %
1	9,09 %	30,56 %	33,33 %

Topic	Panel	Type of Action	Proposal number	Acronym
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248978	ACT-Africa
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248978	ACT-Africa
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248978	ACT-Africa
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248978	ACT-Africa
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248978	ACT-Africa
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248978	ACT-Africa
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248978	ACT-Africa
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248978	ACT-Africa
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248873	ACT4KIDS-TB
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248873	ACT4KIDS-TB
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248873	ACT4KIDS-TB
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248873	ACT4KIDS-TB
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248873	ACT4KIDS-TB
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248882	ASAQ-PAC
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248882	ASAQ-PAC
HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage	HORIZON-JU-RIA	101248882	ASAQ-PAC

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-GH-EDCTP3-2025-04-CH-01-two-stage	HORIZON-JU-RIA	101249026	TARGET
--	--	----------------	-----------	--------

ANNEX 7 Table 7: List of participants in evaluated proposals

Title	Status	Participant role	Country	Business name	Legal name
Using Artificial Intelligence to Develop Affordable and Efficient Clinical Data Management Systems to Accelerate Quality Clinical Research Output from Africa	Below available budget	Coordinator	ZA	WHC	WITS HEALTH CONSORTIUM (PTY) LTD
Using Artificial Intelligence to Develop Affordable and Efficient Clinical Data Management Systems to Accelerate Quality Clinical Research Output from Africa	Below available budget	Participant	ZA	Bioinformatico (Pty) LTD	Bioinformatico
Using Artificial Intelligence to Develop Affordable and Efficient Clinical Data Management Systems to Accelerate Quality Clinical Research Output from Africa	Below available budget	Participant	ZA	UNIVERSITY OF THE WITWATERS	UNIVERSITY OF THE WITWATERS
Using Artificial Intelligence to Develop Affordable and Efficient Clinical Data Management Systems to Accelerate Quality Clinical Research Output from Africa	Below available budget	Participant	ZW	University of Zimbabwe	University of Zimbabwe
Using Artificial Intelligence to Develop Affordable and Efficient Clinical Data Management Systems to Accelerate Quality Clinical Research Output from Africa	Below available budget	Participant	DE	LMU MUENCHEN	LUDWIG-MAXIMILIANS-UNIVERSITAET
Using Artificial Intelligence to Develop Affordable and Efficient Clinical Data Management Systems to Accelerate Quality Clinical Research Output from Africa	Below available budget	Participant - AF	DE	LMU KLINIKUM	KLINIKUM DER LUDWIG-MAXIMILIANS
Using Artificial Intelligence to Develop Affordable and Efficient Clinical Data Management Systems to Accelerate Quality Clinical Research Output from Africa	Below available budget	Participant	FR	INSERM	INSTITUT NATIONAL DE LA SANTE ET
Using Artificial Intelligence to Develop Affordable and Efficient Clinical Data Management Systems to Accelerate Quality Clinical Research Output from Africa	Below available budget	Participant - AF	FR	UBx	UNIVERSITE DE BORDEAUX
Actiphage-supported Clinical Tools for Knowledge-driven Innovations in Diagnostic Solutions for TB in young children	Below available budget	Coordinator	BE	ITM	INSTITUUT VOOR TROPISCHE
Actiphage-supported Clinical Tools for Knowledge-driven Innovations in Diagnostic Solutions for TB in young children	Below available budget	Participant	ZA	DTTC/SU	STELLENBOSCH UNIVERSITY
Actiphage-supported Clinical Tools for Knowledge-driven Innovations in Diagnostic Solutions for TB in young children	Below available budget	Participant	ZA	UCT	UNIVERSITY OF CAPE TOWN
Actiphage-supported Clinical Tools for Knowledge-driven Innovations in Diagnostic Solutions for TB in young children	Below available budget	Participant	BJ	CNHPP	CENTRE NATIONAL HOSPITALIER
Actiphage-supported Clinical Tools for Knowledge-driven Innovations in Diagnostic Solutions for TB in young children	Below available budget	Participant	KE	AKU	AGA KHAN UNIVERSITY KENYA
Actiphage-supported Clinical Tools for Knowledge-driven Innovations in Diagnostic Solutions for TB in young children	Below available budget	Participant	KE	KWTRP	HEALTH RESEARCH OPERATIONS
Advancing child-friendly artesunate-amodiaquine taste mask coated micro pellets to combat the threat of artemisinin resistant malaria in Africa	Main list	Coordinator	UK	UOXF	THE CHANCELLOR, MASTERS AND
Advancing child-friendly artesunate-amodiaquine taste mask coated micro pellets to combat the threat of artemisinin resistant malaria in Africa	Main list	Participant	UK	UNIVERSITY OF HERTEFORDS	THE UNIVERSITY OF HERTEFORDSHIRE
Advancing child-friendly artesunate-amodiaquine taste mask coated micro pellets to combat the threat of artemisinin resistant malaria in Africa	Main list	Participant	UK	Fluid Pharma	Fluid Pharma Ltd

Advancing child-friendly artesunate-amodiaquine taste mask coated micro pellets to combat the threat of artemisinin resistant malaria in Africa	Main list	Participant	MW	KAMUZU UNIVERSITY OF HEALTH CLINSEARCH	KAMUZU UNIVERSITY OF HEALTH CLINSEARCH
Advancing child-friendly artesunate-amodiaquine taste mask coated micro pellets to combat the threat of artemisinin resistant malaria in Africa	Main list	Participant	FR		
FIELD TESTING OF ADDICAD: AN INNOVATIVE DIAGNOSTIC TEST FOR TUBERCULOSIS THAT ADDS TO CAD	Main list	Coordinator	ZA	SU	STELLENBOSCH UNIVERSITY
FIELD TESTING OF ADDICAD: AN INNOVATIVE DIAGNOSTIC TEST FOR TUBERCULOSIS THAT ADDS TO CAD	Main list	Participant	ZA	LifeSADX	LifeSADX (Pty) Ltd
FIELD TESTING OF ADDICAD: AN INNOVATIVE DIAGNOSTIC TEST FOR TUBERCULOSIS THAT ADDS TO CAD	Main list	Participant	UK	LSHTM	LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
FIELD TESTING OF ADDICAD: AN INNOVATIVE DIAGNOSTIC TEST FOR TUBERCULOSIS THAT ADDS TO CAD	Main list	Participant	NA	UNAM	UNIVERSITY OF NAMIBIA UNAM
FIELD TESTING OF ADDICAD: AN INNOVATIVE DIAGNOSTIC TEST FOR TUBERCULOSIS THAT ADDS TO CAD	Main list	Participant	NL	Delft Imaging Systems BV	DELFT IMAGING SYSTEMS BV
FIELD TESTING OF ADDICAD: AN INNOVATIVE DIAGNOSTIC TEST FOR TUBERCULOSIS THAT ADDS TO CAD	Main list	Participant	DE	LINQ	LINQ MANAGEMENT GMBH
Evaluating pharmacokinetics, acceptability and tolerability of novel azithromycin orally disintegrating mini tablets in comparison to standard suspension and defining a roadmap towards access	Below Threshold	Coordinator	UK	CITY	CITY ST GEORGES UNIVERSITY OF LONDON
Evaluating pharmacokinetics, acceptability and tolerability of novel azithromycin orally disintegrating mini tablets in comparison to standard suspension and defining a roadmap towards access	Below Threshold	Participant	MU	AFRICA CLINICAL RESEARCH	Africa Clinical Research Network
Evaluating pharmacokinetics, acceptability and tolerability of novel azithromycin orally disintegrating mini tablets in comparison to standard suspension and defining a roadmap towards access	Below Threshold	Participant	ZA	SU UNIVERSITY OF	STELLENBOSCH UNIVERSITY
Evaluating pharmacokinetics, acceptability and tolerability of novel azithromycin orally disintegrating mini tablets in comparison to standard suspension and defining a roadmap towards access	Below Threshold	Participant	IT	FONDAZIONE PENTA ETS	FONDAZIONE PENTA ETS
Evaluating pharmacokinetics, acceptability and tolerability of novel azithromycin orally disintegrating mini tablets in comparison to standard suspension and defining a roadmap towards access	Below Threshold	Participant	CH	AXMED AG	Axmed AG
Evaluating pharmacokinetics, acceptability and tolerability of novel azithromycin orally disintegrating mini tablets in comparison to standard suspension and defining a roadmap towards access	Below Threshold	Participant	CH	UNIVERSITAT BASEL	UNIVERSITAT BASEL
Evaluating pharmacokinetics, acceptability and tolerability of novel azithromycin orally disintegrating mini tablets in comparison to standard suspension and defining a roadmap towards access	Below Threshold	Participant	TZ	IFAKARA HEALTH INSTITUTE	THE REGISTERED TRUSTEES OF
Evaluating pharmacokinetics, acceptability and tolerability of novel azithromycin orally disintegrating mini tablets in comparison to standard suspension and defining a roadmap towards access	Below Threshold	Participant - AP	CH	WHO	WORLD HEALTH ORGANIZATION
Does BCG vaccine reduce mortality among seniors over 50 years of age in two countries in Sub-Saharan Africa? Two randomised controlled trials (BCG-SeniorS-Africa)	Below Threshold	Coordinator	DK	SDU	SYDDANSK UNIVERSITET
Does BCG vaccine reduce mortality among seniors over 50 years of age in two countries in Sub-Saharan Africa? Two randomised controlled trials (BCG-SeniorS-Africa)	Below Threshold	Participant	GH	Navrongo Health Research	Navrongo Health Research Centre
Does BCG vaccine reduce mortality among seniors over 50 years of age in two countries in Sub-Saharan Africa? Two randomised controlled trials (BCG-SeniorS-Africa)	Below Threshold	Participant	GW	INASA	INSTITUTO NACIONAL DE SAUDE
Accelerating Capillary blood Self-Collection using the C2K device for Expanded Screening, and Surveillance of Infectious Diseases in Sub-Saharan Africa	Below Threshold	Coordinator	BE	ITM	INSTITUUT VOOR TROPISCHE

Accelerating Capillary blood Self-Collection using the C2K device for Expanded Screening, and Surveillance of Infectious Diseases in Sub-Saharan Africa	Below Threshold	Participant	BE	Protex Healthcare	Protex Healthcare NV
Accelerating Capillary blood Self-Collection using the C2K device for Expanded Screening, and Surveillance of Infectious Diseases in Sub-Saharan Africa	Below Threshold	Participant - AF	NG	Protex Healthcare West Africa	Protex Healthcare West Africa
Accelerating Capillary blood Self-Collection using the C2K device for Expanded Screening, and Surveillance of Infectious Diseases in Sub-Saharan Africa	Below Threshold	Participant	BE	VOXDALE	VOXDALE
Accelerating Capillary blood Self-Collection using the C2K device for Expanded Screening, and Surveillance of Infectious Diseases in Sub-Saharan Africa	Below Threshold	Participant	GN	Centre National de Formation et	CENTRE NATIONAL DE FORMATION ET
Accelerating Capillary blood Self-Collection using the C2K device for Expanded Screening, and Surveillance of Infectious Diseases in Sub-Saharan Africa	Below Threshold	Participant	ZM	ZAMBART	ZAMBART
Field Evaluation and Randomised Controlled Trial of a Dried Spot Kit for Improved Diagnosis and Surveillance of AMR Bacterial Infections in Malawi, and Ghana	Below available budget	Coordinator	UK	LIVERPOOL SCHOOL OF TROPICAL	LIVERPOOL SCHOOL OF TROPICAL
Field Evaluation and Randomised Controlled Trial of a Dried Spot Kit for Improved Diagnosis and Surveillance of AMR Bacterial Infections in Malawi, and Ghana	Below available budget	Participant	MW	MALAWI-LIVERPOOL-WELL COME	MALAWI-LIVERPOOL-WELL COME
Field Evaluation and Randomised Controlled Trial of a Dried Spot Kit for Improved Diagnosis and Surveillance of AMR Bacterial Infections in Malawi, and Ghana	Below available budget	Participant	GH	Navrongo Health Research	Navrongo Health Research Centre
Field Evaluation and Randomised Controlled Trial of a Dried Spot Kit for Improved Diagnosis and Surveillance of AMR Bacterial Infections in Malawi, and Ghana	Below available budget	Participant	UK	CPI	CENTRE FOR PROCESS INNOVATION
Field Evaluation and Randomised Controlled Trial of a Dried Spot Kit for Improved Diagnosis and Surveillance of AMR Bacterial Infections in Malawi, and Ghana	Below available budget	Participant	ZA	MAA GLOBAL	MAA GLOBAL
Field Evaluation and Randomised Controlled Trial of a Dried Spot Kit for Improved Diagnosis and Surveillance of AMR Bacterial Infections in Malawi, and Ghana	Below available budget	Participant - AP	ET	Africa Centres for Disease Control and	AFRICA CENTRES FOR DISEASE
Field Evaluation and Randomised Controlled Trial of a Dried Spot Kit for Improved Diagnosis and Surveillance of AMR Bacterial Infections in Malawi, and Ghana	Below available budget	Participant - AP	UK	LGC	LGC LIMITED
Field Evaluation and Randomised Controlled Trial of a Dried Spot Kit for Improved Diagnosis and Surveillance of AMR Bacterial Infections in Malawi, and Ghana	Below available budget	Participant - AP	US	SFA FOUNDATION	SCIENCE FOR AFRICA FOUNDATION
MULTICENTRE, INTERVENTIONAL, OPEN-LABEL PHASE 2/3 STUDY OF THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS OF INTRANASAL ARTESUNATE IN PATIENTS WITH UNCOMPLICATED AND	Below Threshold	Coordinator	FR	EUNOVIS	EUNOVIS
MULTICENTRE, INTERVENTIONAL, OPEN-LABEL PHASE 2/3 STUDY OF THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS OF INTRANASAL ARTESUNATE IN PATIENTS WITH UNCOMPLICATED AND	Below Threshold	Participant	ML	USTTB	UNIVERSITE DES SCIENCES DES
MULTICENTRE, INTERVENTIONAL, OPEN-LABEL PHASE 2/3 STUDY OF THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS OF INTRANASAL ARTESUNATE IN PATIENTS WITH UNCOMPLICATED AND	Below Threshold	Participant	GM	Medical Research Council Unit	Medical Research Council Unit The
MULTICENTRE, INTERVENTIONAL, OPEN-LABEL PHASE 2/3 STUDY OF THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS OF INTRANASAL ARTESUNATE IN PATIENTS WITH UNCOMPLICATED AND	Below Threshold	Participant	MW	KAMUZU UNIVERSITY OF HEALTH	KAMUZU UNIVERSITY OF HEALTH
MULTICENTRE, INTERVENTIONAL, OPEN-LABEL PHASE 2/3 STUDY OF THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS OF INTRANASAL ARTESUNATE IN PATIENTS WITH UNCOMPLICATED AND	Below Threshold	Participant	SE	KI	KAROLINSKA INSTITUTET
MULTICENTRE, INTERVENTIONAL, OPEN-LABEL PHASE 2/3 STUDY OF THE EFFICACY, SAFETY, TOLERABILITY, PHARMACOKINETICS OF INTRANASAL ARTESUNATE IN PATIENTS WITH UNCOMPLICATED AND	Below Threshold	Participant	UK	UOXF	THE CHANCELLOR, MASTERS AND
FIRST HIGHLY SENSITIVE MALARIA DIAGNOSTICS FOR ASYMPTOMATIC LOW-DENSITY INFECTIONS AT POINT-OF-CARE (INFECTOTEST)	Below available budget	Coordinator	DE	Zendia GmbH	Zendia GmbH

FIRST HIGHLY SENSITIVE MALARIA DIAGNOSTICS FOR ASYMPTOMATIC LOW-DENSITY INFECTIONS AT POINT-OF-CARE (INFECTOTEST)	Below available budget	Participant	BF	CRUN	Clinical Research Unit of Nanoro
FIRST HIGHLY SENSITIVE MALARIA DIAGNOSTICS FOR ASYMPTOMATIC LOW-DENSITY INFECTIONS AT POINT-OF-CARE (INFECTOTEST)	Below available budget	Participant	DE	UPT Optik Wodak GmbH	UPT Optik Wodak GmbH
FIRST HIGHLY SENSITIVE MALARIA DIAGNOSTICS FOR ASYMPTOMATIC LOW-DENSITY INFECTIONS AT POINT-OF-CARE (INFECTOTEST)	Below available budget	Participant	UK	LSHTM	LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
FIRST HIGHLY SENSITIVE MALARIA DIAGNOSTICS FOR ASYMPTOMATIC LOW-DENSITY INFECTIONS AT POINT-OF-CARE (INFECTOTEST)	Below available budget	Participant	ML	USTTB	UNIVERSITE DES SCIENCES DES TROPES
FIRST HIGHLY SENSITIVE MALARIA DIAGNOSTICS FOR ASYMPTOMATIC LOW-DENSITY INFECTIONS AT POINT-OF-CARE (INFECTOTEST)	Below available budget	Participant	FR	CNRS	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Forging Innovative and Lasting Pathways for the Elimination of Paediatric HIV through Prevention, Early Testing, and Treatment	Below Threshold	Coordinator	DE	LMU	LUDWIG-MAXIMILIANS-UNIVERSITAET MÜNCHEN
Forging Innovative and Lasting Pathways for the Elimination of Paediatric HIV through Prevention, Early Testing, and Treatment	Below Threshold	Participant - AF	DE	LMU KLINIKUM	KLINIKUM DER LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN
Forging Innovative and Lasting Pathways for the Elimination of Paediatric HIV through Prevention, Early Testing, and Treatment	Below Threshold	Participant	MZ	INS	Instituto Nacional de Saúde
Forging Innovative and Lasting Pathways for the Elimination of Paediatric HIV through Prevention, Early Testing, and Treatment	Below Threshold	Participant	NG	HJFMRI Ltd/Gte	HJFMRI Ltd/Gte
Forging Innovative and Lasting Pathways for the Elimination of Paediatric HIV through Prevention, Early Testing, and Treatment	Below Threshold	Participant	CM	R4D International	Research for Development International
Forging Innovative and Lasting Pathways for the Elimination of Paediatric HIV through Prevention, Early Testing, and Treatment	Below Threshold	Participant	CM	CIRCB	Centre International de Recherche en Biologie
Forging Innovative and Lasting Pathways for the Elimination of Paediatric HIV through Prevention, Early Testing, and Treatment	Below Threshold	Participant	TZ	NIMR	NATIONAL INSTITUTE FOR MEDICAL RESEARCH
Forging Innovative and Lasting Pathways for the Elimination of Paediatric HIV through Prevention, Early Testing, and Treatment	Below Threshold	Participant	DE	KLINIKUM DER UNIVERSITÄT ZÜRICH	KLINIKUM DER UNIVERSITÄT ZÜRICH
Forging Innovative and Lasting Pathways for the Elimination of Paediatric HIV through Prevention, Early Testing, and Treatment	Below Threshold	Participant	PT	EGAS MONIZ	EGAS MONIZ COOPERATIVA DE ENSINO
Forging Innovative and Lasting Pathways for the Elimination of Paediatric HIV through Prevention, Early Testing, and Treatment	Below Threshold	Participant	KE	IAVI AFRICA	IAVI AFRICA LIMITED
ENHANCING EQUITABLE VACCINE ACCESS THROUGH REDUCED-DOSE MPOX VACCINATION USING VAX-ID IN SUB-SAHARAN AFRICA	Below available budget	Coordinator	BE	UANTWERPEN	UNIVERSITEIT ANTWERPEN
ENHANCING EQUITABLE VACCINE ACCESS THROUGH REDUCED-DOSE MPOX VACCINATION USING VAX-ID IN SUB-SAHARAN AFRICA	Below available budget	Participant	CD	UNIKIN	UNIVERSITE DE KINSHASA
ENHANCING EQUITABLE VACCINE ACCESS THROUGH REDUCED-DOSE MPOX VACCINATION USING VAX-ID IN SUB-SAHARAN AFRICA	Below available budget	Participant	IT	FONDAZIONE PENTA ETS	FONDAZIONE PENTA ETS
ENHANCING EQUITABLE VACCINE ACCESS THROUGH REDUCED-DOSE MPOX VACCINATION USING VAX-ID IN SUB-SAHARAN AFRICA	Below available budget	Participant	KE	ACE Research	AFRICA CLINICAL RESEARCH
ENHANCING EQUITABLE VACCINE ACCESS THROUGH REDUCED-DOSE MPOX VACCINATION USING VAX-ID IN SUB-SAHARAN AFRICA	Below available budget	Participant	BE	IDEVAX	IDEVAX

ENHANCING EQUITABLE VACCINE ACCESS THROUGH REDUCED-DOSE MPOX VACCINATION USING VAX-ID IN SUB-SAHARAN AFRICA	Below available budget	Participant	UK	UNIVERSITY COLLEGE LONDON	UNIVERSITY COLLEGE LONDON
AFFORDABLE NEUROIMAGING FOR DIAGNOSIS AND MONITORING OF INFECTIOUS DISEASES IN SUB-SAHARAN AFRICA	Below available budget	Coordinator	ES	CSIC	AGENCIA ESTATAL CONSEJO
AFFORDABLE NEUROIMAGING FOR DIAGNOSIS AND MONITORING OF INFECTIOUS DISEASES IN SUB-SAHARAN AFRICA	Below available budget	Participant	UG	MUST	MBARARA UNIVERSITY OF SCIENCE AND
AFFORDABLE NEUROIMAGING FOR DIAGNOSIS AND MONITORING OF INFECTIOUS DISEASES IN SUB-SAHARAN AFRICA	Below available budget	Participant	NL	Leiden University Medical Center	ACADEMISCH ZIEKENHUIS LEIDEN
AFFORDABLE NEUROIMAGING FOR DIAGNOSIS AND MONITORING OF INFECTIOUS DISEASES IN SUB-SAHARAN AFRICA	Below available budget	Participant	ES	PHYSIO MRI TECH SL	PHYSIO MRI TECH SL
AFFORDABLE NEUROIMAGING FOR DIAGNOSIS AND MONITORING OF INFECTIOUS DISEASES IN SUB-SAHARAN AFRICA	Below available budget	Participant	ZA	UCT	UNIVERSITY OF CAPE TOWN
AFFORDABLE NEUROIMAGING FOR DIAGNOSIS AND MONITORING OF INFECTIOUS DISEASES IN SUB-SAHARAN AFRICA	Below available budget	Participant	MZ	UEM	UNIVERSIDADE EDUARDO MONDLANE
Point-of-care Lab-on-Chip Detection of Host Response in Febrile Illness for Diagnosis and Etiology Research	Below available budget	Coordinator	UK	IMPERIAL COLLEGE OF SCIENCE	IMPERIAL COLLEGE OF SCIENCE
Point-of-care Lab-on-Chip Detection of Host Response in Febrile Illness for Diagnosis and Etiology Research	Below available budget	Participant	UK	ProtonDx	ProtonDx Ltd
Point-of-care Lab-on-Chip Detection of Host Response in Febrile Illness for Diagnosis and Etiology Research	Below available budget	Participant	GH	UNIVERSITY OF GHANA	UNIVERSITY OF GHANA
Point-of-care Lab-on-Chip Detection of Host Response in Febrile Illness for Diagnosis and Etiology Research	Below available budget	Participant	BF	CNRST/IRSS-DRCO/Clinical Research Unit	Clinical Research Unit of Nanoro
Point-of-care Lab-on-Chip Detection of Host Response in Febrile Illness for Diagnosis and Etiology Research	Below available budget	Participant	NL	STICHTING AMSTERDAM UMC	STICHTING AMSTERDAM UMC
Point-of-care Lab-on-Chip Detection of Host Response in Febrile Illness for Diagnosis and Etiology Research	Below available budget	Participant	UK	LSHTM	LONDON SCHOOL OF HYGIENE AND
Prospective evaluation and refinement of novel biomarker-based point-of-care tests for the diagnosis of tuberculous meningitis in children	Main list	Coordinator	ZA	SU	STELLENBOSCH UNIVERSITY
Prospective evaluation and refinement of novel biomarker-based point-of-care tests for the diagnosis of tuberculous meningitis in children	Main list	Participant	DE	LINQ	LINQ MANAGEMENT GMBH
Prospective evaluation and refinement of novel biomarker-based point-of-care tests for the diagnosis of tuberculous meningitis in children	Main list	Participant	ZM	UNZA	UNIVERSITY OF ZAMBIA
Prospective evaluation and refinement of novel biomarker-based point-of-care tests for the diagnosis of tuberculous meningitis in children	Main list	Participant	ZW	UZ	University of Zimbabwe
Prospective evaluation and refinement of novel biomarker-based point-of-care tests for the diagnosis of tuberculous meningitis in children	Main list	Participant	ZA	LifeSADx	LifeSADx (Pty) Ltd
Prospective evaluation and refinement of novel biomarker-based point-of-care tests for the diagnosis of tuberculous meningitis in children	Main list	Participant	FR	IMAGINE	IMAGINE INSTITUT DES MALADIES
PARAsitic diseases of sub-Saharan Africa early detection, identification and management with Artificial Intelligence (ParasiteAID)	Below available budget	Coordinator	ES	UPM	UNIVERSIDAD POLITECNICA DE MADRID

PARAsitic diseases of sub-Saharan afrlca early deTecton, IDentification and management with Artificial Intelligence (ParasiteAID)	Below available budget	Participant	ZA	National Health Laboratory Services	NATIONAL HEALTH LABORATORY
PARAsitic diseases of sub-Saharan afrlca early deTecton, IDentification and management with Artificial Intelligence (ParasiteAID)	Below available budget	Participant	ES	Tamia Innova Lab	Tamia Innova Lab
PARAsitic diseases of sub-Saharan afrlca early deTecton, IDentification and management with Artificial Intelligence (ParasiteAID)	Below available budget	Participant	KE	KEMRI	KENYA MEDICAL RESEARCH
PARAsitic diseases of sub-Saharan afrlca early deTecton, IDentification and management with Artificial Intelligence (ParasiteAID)	Below available budget	Participant	GH	KNUST	KWAME NKRUMAH UNIVERSITY OF
PARAsitic diseases of sub-Saharan afrlca early deTecton, IDentification and management with Artificial Intelligence (ParasiteAID)	Below available budget	Participant	EG	CAIRO UNIVERSITY	CAIRO UNIVERSITY
PARAsitic diseases of sub-Saharan afrlca early deTecton, IDentification and management with Artificial Intelligence (ParasiteAID)	Below available budget	Participant	ET	ARMAUER HANSEN RESEARCH	ARMAUER HANSEN RESEARCH
PARAsitic diseases of sub-Saharan afrlca early deTecton, IDentification and management with Artificial Intelligence (ParasiteAID)	Below available budget	Participant	ES	AUSTRALO	AUSTRALO INTERINNOV MARKETING
PARAsitic diseases of sub-Saharan afrlca early deTecton, IDentification and management with Artificial Intelligence (ParasiteAID)	Below available budget	Participant	KE	OMODI, AGASNA, ODIEMBO	OMODI, AGASNA, ODIEMBO
PARAsitic diseases of sub-Saharan afrlca early deTecton, IDentification and management with Artificial Intelligence (ParasiteAID)	Below available budget	Participant	SN	YUX Design	YUX SAS
PARAsitic diseases of sub-Saharan afrlca early deTecton, IDentification and management with Artificial Intelligence (ParasiteAID)	Below available budget	Participant	CD	UCB	UNIVERSITE CATHOLIQUE DE BUKAVU
PARAsitic diseases of sub-Saharan afrlca early deTecton, IDentification and management with Artificial Intelligence (ParasiteAID)	Below available budget	Participant	GN	World Health Organization	World Health Organization
PARAsitic diseases of sub-Saharan afrlca early deTecton, IDentification and management with Artificial Intelligence (ParasiteAID)	Below available budget	Participant	NG	Leprosy and Tuberculosis Relief Initiative	Leprosy and Tuberculosis Relief Initiative
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Below Threshold	Coordinator	UK	USTAN	THE UNIVERSITY COURT OF THE
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Below Threshold	Participant	TZ	NIMR	NATIONAL INSTITUTE FOR MEDICAL
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Below Threshold	Participant	GH	UDS CCEIR	UNIVERSITY FOR DEVELOPMENT
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Below Threshold	Participant	UG	MAKERERE UNIVERSITY LUNG	MAKERERE UNIVERSITY LUNG
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Below Threshold	Participant	CD	UCB	UNIVERSITE CATHOLIQUE DE BUKAVU
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Below Threshold	Participant	GA	CERMEL	Centre de Recherches Medicales de
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Below Threshold	Participant	GH	UNIVERSITY OF GHANA	UNIVERSITY OF GHANA
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Below Threshold	Participant	UK	VERTEBRATE ANTIBODIES LIMITED	VERTEBRATE ANTIBODIES LIMITED

REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Below Threshold	Participant	FR	PANTHER	PANDEMIC PREPAREDNESS PLATFORM
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Below Threshold	Participant	TZ	INUKA Africa	INUKA Africa
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Below Threshold	Participant	UG	Adroit Biomedical and Bio-Entrepreneurship	Adroit Biomedical & Bio-Entrepreneurship
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Below Threshold	Participant	UK	Mologic	MOLOGIC LTD
REACHING ALL WITH A RAPID DETECTION TEST FOR TUBERCULOSIS (R-RDT4TB)	Below Threshold	Participant - AP	ET	AFRICA CENTRES FOR DISEASE	AFRICA CENTRES FOR DISEASE
Rapid Research in Next-Generation Diagnostics Development for Drug-Resistant Tuberculosis	Main list	Coordinator	DE	UKHD	UNIVERSITÄTSKLINIKUM HEIDELBERG
Rapid Research in Next-Generation Diagnostics Development for Drug-Resistant Tuberculosis	Main list	Participant	ZA	SU UNIVERSITY OF	STELLENBOSCH UNIVERSITY
Rapid Research in Next-Generation Diagnostics Development for Drug-Resistant Tuberculosis	Main list	Participant	CH	Swiss TPH	SCHWEIZERISCHE S TROPEN UND PUBLIC
Rapid Research in Next-Generation Diagnostics Development for Drug-Resistant Tuberculosis	Main list	Participant	GE	NCTLD	NATIONAL CENTER FOR TUBERCULOSIS
Recurrent TB Screening and Prevention Study	Main list	Coordinator	NL	AUMC	STICHTING AMSTERDAM UMC
Recurrent TB Screening and Prevention Study	Main list	Participant - AF	NL	AIGHD	STICHTING AMSTERDAM INSTITUTE FOR
Recurrent TB Screening and Prevention Study	Main list	Participant	UG	IDI	THE INFECTIOUS DISEASES
Recurrent TB Screening and Prevention Study	Main list	Participant	ZA	SU	STELLENBOSCH UNIVERSITY
Recurrent TB Screening and Prevention Study	Main list	Participant	UK	USTAN	THE UNIVERSITY COURT OF THE
SEASONAL MASS VACCINATION WITH MASS DRUG ADMINISTRATION FOR MALARIA ELIMINATION	Below available budget	Coordinator	UK	LSHTM	LONDON SCHOOL OF HYGIENE AND
SEASONAL MASS VACCINATION WITH MASS DRUG ADMINISTRATION FOR MALARIA ELIMINATION	Below available budget	Participant	BF	CENTRE NATIONAL DE RECHERCHE	CENTRE NATIONAL DE RECHERCHE
SEASONAL MASS VACCINATION WITH MASS DRUG ADMINISTRATION FOR MALARIA ELIMINATION	Below available budget	Participant	BE	ITM	INSTITUUT VOOR TROPISCHE
SEASONAL MASS VACCINATION WITH MASS DRUG ADMINISTRATION FOR MALARIA ELIMINATION	Below available budget	Participant	UK	UOXF	THE CHANCELLOR, MASTERS AND
SEASONAL MASS VACCINATION WITH MASS DRUG ADMINISTRATION FOR MALARIA ELIMINATION	Below available budget	Participant	UK	IMPERIAL COLLEGE OF SCIENCE	IMPERIAL COLLEGE OF SCIENCE
SWAB-IMPACT: Swab-Based Molecular Testing for Impact on TB Diagnosis and Treatment	Main list	Coordinator	ZA	THE AURUM INSTITUTE NPC	THE AURUM INSTITUTE NPC

SWAB-IMPACT: Swab-Based Molecular Testing for Impact on TB Diagnosis and Treatment	Main list	Participant	DE	UKHD	UNIVERSITÄTS KLINIKUM HEIDELBERG
SWAB-IMPACT: Swab-Based Molecular Testing for Impact on TB Diagnosis and Treatment	Main list	Participant	ZM	Centre for Infectious Disease	Centre for Infectious Disease
TRANSFORMING ADVANCED HIV CARE WITH A TARGETED INTERVENTION FOR CMV (TACTIC): A Phase 3 Randomised Controlled Trial	Below Threshold	Coordinator	UK	LSHTM	LONDON SCHOOL OF HYGIENE AND
TRANSFORMING ADVANCED HIV CARE WITH A TARGETED INTERVENTION FOR CMV (TACTIC): A Phase 3 Randomised Controlled Trial	Below Threshold	Participant	ZA	WHC	WITS HEALTH CONSORTIUM (PTY) LTD
TRANSFORMING ADVANCED HIV CARE WITH A TARGETED INTERVENTION FOR CMV (TACTIC): A Phase 3 Randomised Controlled Trial	Below Threshold	Participant	UG	THE INFECTIOUS DISEASES	THE INFECTIOUS DISEASES
PIONEERING ADJUVANT IMMUNOTHERAPY TO PROMOTE LUNG FUNCTION RECOVERY AMONG PATIENTS WITH DRUG SUSCEPTIBLE-TUBERCULOSIS IN HIGH BURDEN COUNTRIES	Below Threshold	Coordinator	DE	EUROPEAN VACCINE INITIATIVE e.V.	EUROPEAN VACCINE INITIATIVE E.V.
PIONEERING ADJUVANT IMMUNOTHERAPY TO PROMOTE LUNG FUNCTION RECOVERY AMONG PATIENTS WITH DRUG SUSCEPTIBLE-TUBERCULOSIS IN HIGH BURDEN COUNTRIES	Below Threshold	Participant	ZA	THE AURUM INSTITUTE NPC	THE AURUM INSTITUTE NPC
PIONEERING ADJUVANT IMMUNOTHERAPY TO PROMOTE LUNG FUNCTION RECOVERY AMONG PATIENTS WITH DRUG SUSCEPTIBLE-TUBERCULOSIS IN HIGH BURDEN COUNTRIES	Below Threshold	Participant	TZ	THE CATHOLIC UNIVERSITY	THE CATHOLIC UNIVERSITY OF HEALTH AND
PIONEERING ADJUVANT IMMUNOTHERAPY TO PROMOTE LUNG FUNCTION RECOVERY AMONG PATIENTS WITH DRUG SUSCEPTIBLE-TUBERCULOSIS IN HIGH BURDEN COUNTRIES	Below Threshold	Participant	UG	MAKERERE	MAKERERE UNIVERSITY
PIONEERING ADJUVANT IMMUNOTHERAPY TO PROMOTE LUNG FUNCTION RECOVERY AMONG PATIENTS WITH DRUG SUSCEPTIBLE-TUBERCULOSIS IN HIGH BURDEN COUNTRIES	Below Threshold	Participant - AP	IN	Open Source Pharma Foundation	Open Source Pharma Foundation
Tuberculosis Diagnostics using Innovative Swab and CAD for Optimized Validation and Enhanced Response for children	Below available budget	Coordinator	UG	WALIMU	WORLD ALLIANCE FOR LUNG AND
Tuberculosis Diagnostics using Innovative Swab and CAD for Optimized Validation and Enhanced Response for children	Below available budget	Participant	MZ	INS	Instituto Nacional de Saúde
Tuberculosis Diagnostics using Innovative Swab and CAD for Optimized Validation and Enhanced Response for children	Below available budget	Participant	DE	UKHD	UNIVERSITÄTS KLINIKUM HEIDELBERG
AI assisted innovative low-cost skin testing model to accelerate person-centered TB prevention services in Tanzania, Mozambique and Uganda.	Main list	Coordinator	NL	KONINKLIJKE NEDERLANDSE F. CENTRALE	KONINKLIJKE NEDERLANDSE CENTRALE
AI assisted innovative low-cost skin testing model to accelerate person-centered TB prevention services in Tanzania, Mozambique and Uganda.	Main list	Participant	TZ	NIMR	NATIONAL INSTITUTE FOR MEDICAL
AI assisted innovative low-cost skin testing model to accelerate person-centered TB prevention services in Tanzania, Mozambique and Uganda.	Main list	Participant	TZ	MKUTA	Mwitikio wa Kudhibiti Kifua Kikuu na Ukirowi
AI assisted innovative low-cost skin testing model to accelerate person-centered TB prevention services in Tanzania, Mozambique and Uganda.	Main list	Participant	MZ	FM	FUNDAÇÃO MANHICA
AI assisted innovative low-cost skin testing model to accelerate person-centered TB prevention services in Tanzania, Mozambique and Uganda.	Main list	Participant	ES	ISGLOBAL	FUNDACION PRIVADA INSTITUTO DE
AI assisted innovative low-cost skin testing model to accelerate person-centered TB prevention services in Tanzania, Mozambique and Uganda.	Main list	Participant	UG	MAKERERE UNIVERSITY LUNG	MAKERERE UNIVERSITY LUNG
AI assisted innovative low-cost skin testing model to accelerate person-centered TB prevention services in Tanzania, Mozambique and Uganda.	Main list	Participant	UG	Mildmay Research Centre Uganda	Mildmay Research Centre Uganda Ltd

AI assisted innovative low-cost skin testing model to accelerate person-centered TB prevention services in Tanzania, Mozambique and Uganda.	Main list	Participant	UK	LSHTM	LONDON SCHOOL OF HYGIENE AND
Leveraging eHealth to Overcome Barriers in NTDs: Enhancing Access to Anthelmintic Treatment for Schistosomiasis and Soil-transmitted Helminths.	Below Threshold	Coordinator	ES	ISCIH	INSTITUTO DE SALUD CARLOS III
Leveraging eHealth to Overcome Barriers in NTDs: Enhancing Access to Anthelmintic Treatment for Schistosomiasis and Soil-transmitted Helminths.	Below Threshold	Participant	FR	PARADEV	PARADEV
Leveraging eHealth to Overcome Barriers in NTDs: Enhancing Access to Anthelmintic Treatment for Schistosomiasis and Soil-transmitted Helminths.	Below Threshold	Participant	FR	UPVD	UNIVERSITE DE PERPIGNAN
Leveraging eHealth to Overcome Barriers in NTDs: Enhancing Access to Anthelmintic Treatment for Schistosomiasis and Soil-transmitted Helminths.	Below Threshold	Participant	ES	SCIENSEED	SCIENSEED SL
Leveraging eHealth to Overcome Barriers in NTDs: Enhancing Access to Anthelmintic Treatment for Schistosomiasis and Soil-transmitted Helminths.	Below Threshold	Participant	ES	ISGLOBAL	FUNDACION PRIVADA INSTITUTO DE
Leveraging eHealth to Overcome Barriers in NTDs: Enhancing Access to Anthelmintic Treatment for Schistosomiasis and Soil-transmitted Helminths.	Below Threshold	Participant	ZM	Levy Mwanawasa Medical	Levy Mwanawasa Medical
Leveraging eHealth to Overcome Barriers in NTDs: Enhancing Access to Anthelmintic Treatment for Schistosomiasis and Soil-transmitted Helminths.	Below Threshold	Participant	BJ	INSTITUT DE RECHERCHE CLINIQUE DU	INSTITUT DE RECHERCHE CLINIQUE DU
Leveraging eHealth to Overcome Barriers in NTDs: Enhancing Access to Anthelmintic Treatment for Schistosomiasis and Soil-transmitted Helminths.	Below Threshold	Participant	ES	SPOTLAB	SPOTLAB SL
Leveraging eHealth to Overcome Barriers in NTDs: Enhancing Access to Anthelmintic Treatment for Schistosomiasis and Soil-transmitted Helminths.	Below Threshold	Participant	NG	ABU	AHMADU BELLO UNIVERSITY
Bran for Resilience Against Childhood Enteric and Diarrhoeal disease and Environmental challenges	Below Threshold	Coordinator	UK	UOB	THE UNIVERSITY OF BIRMINGHAM
Bran for Resilience Against Childhood Enteric and Diarrhoeal disease and Environmental challenges	Below Threshold	Participant	ML	USTTB	UNIVERSITE DES SCIENCES DES
Bran for Resilience Against Childhood Enteric and Diarrhoeal disease and Environmental challenges	Below Threshold	Participant	ML	Ecole Nationale d'Ingenieurs d'Ingenieurs	Ecole Nationale d'Ingenieurs d'Ingenieurs
Bran for Resilience Against Childhood Enteric and Diarrhoeal disease and Environmental challenges	Below Threshold	Participant	DK	UCPH	KOBENHAVNS UNIVERSITET
Bran for Resilience Against Childhood Enteric and Diarrhoeal disease and Environmental challenges	Below Threshold	Participant	ES	ACH	FUNDACION ACCION CONTRA EL
Bran for Resilience Against Childhood Enteric and Diarrhoeal disease and Environmental challenges	Below Threshold	Participant	CZ	PEOPLE IN NEED	CLOVEK V TISNI OPS
Bran for Resilience Against Childhood Enteric and Diarrhoeal disease and Environmental challenges	Below Threshold	Participant	UK	Element-C Ltd	Element-C Ltd
Novel Interventions to Identify and Control Diarrhoeal Diseases in Sub-Saharan Africa	Main list	Coordinator	UK	THE UNIVERSITY OF	THE UNIVERSITY OF NOTTINGHAM
Novel Interventions to Identify and Control Diarrhoeal Diseases in Sub-Saharan Africa	Main list	Participant	UG	THE INFECTIOUS DISEASES	THE INFECTIOUS DISEASES
Novel Interventions to Identify and Control Diarrhoeal Diseases in Sub-Saharan Africa	Main list	Participant	ZA	Jembi Health Systems	Jembi Health Systems

Novel Interventions to Identify and Control Diarrhoeal Diseases in Sub-Saharan Africa	Main list	Participant	ET	Addis Ababa City Administration Health Bureau	Addis Ababa City Administration Health Bureau
Novel Interventions to Identify and Control Diarrhoeal Diseases in Sub-Saharan Africa	Main list	Participant	IT	UNIPG	UNIVERSITA DEGLI STUDI DI PERUGIA
Novel Interventions to Identify and Control Diarrhoeal Diseases in Sub-Saharan Africa	Main list	Participant	ES	Causal Foundry	Causal Foundry Spain SL
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Coordinator	IT	FGB	FONDAZIONE PER LA RICERCA
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Participant	UG	MAK	MAKERERE UNIVERSITY
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Participant	UK	CU	CRANFIELD UNIVERSITY
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Participant - AF	NG	FULAFIA	FEDERAL UNIVERSITY LAKE
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Participant	UK	ULEEDS	UNIVERSITY OF LEEDS
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Participant	UK	LSHTM	LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Participant	NG	UA	UNIVERSITY OF ABUJA
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Participant	KE	APHRC	AFRICAN POPULATION & HEALTH RESEARCH CENTER
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Participant	GH	TREND	Training, Research and Networking for Development
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Participant	SN	UGB	UNIVERSITE GASTON BERGE
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Participant	NL	IHE DELFT	STICHTING IHE DELFT INSTITUTE FOR WATER AND ENVIRONMENT
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Participant	MZ	FM	FUNDACAO MANHICA
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Participant	NG	PPNL	PHILLIPS PHARMACEUTICALS (NIGERIA) LTD
DIARRHOEAL-PREPAREDNESS AND STRATEGIES FOR MANAGING ACCELERATED RESPONSIVE INTERVENTIONS	Below Threshold	Participant	NG	BUTH	BINGHAM UNIVERSITY TEACHING HOSPITAL
Tackling and investigating Escherichia coli Induced Diarrheal Diseases in Central and East Africa (ECOLI-CEA)	Below Threshold	Coordinator	IT	R-EVOWW	R-EVOLUTION WORLDWIDE SCI IMPRESA
Tackling and investigating Escherichia coli Induced Diarrheal Diseases in Central and East Africa (ECOLI-CEA)	Below Threshold	Participant	CD	UNIKIN	UNIVERSITE DE KINSHASA
Tackling and investigating Escherichia coli Induced Diarrheal Diseases in Central and East Africa (ECOLI-CEA)	Below Threshold	Participant	CG	FONDATION CONGOLAISE POUR LA RECHERCHE	FONDATION CONGOLAISE POUR LA RECHERCHE

Tackling and investigating Escherichia coli Induced Diarrheal Diseases in Central and East Africa (ECOLI-CEA)	Below Threshold	Participant	FR	IP	INSTITUT PASTEUR
Tackling and investigating Escherichia coli Induced Diarrheal Diseases in Central and East Africa (ECOLI-CEA)	Below Threshold	Participant	BI	UB	UNIVERSITE DU BURUNDI
Tackling and investigating Escherichia coli Induced Diarrheal Diseases in Central and East Africa (ECOLI-CEA)	Below Threshold	Participant	KE	ILRI	International Livestock Research
Tackling and investigating Escherichia coli Induced Diarrheal Diseases in Central and East Africa (ECOLI-CEA)	Below Threshold	Participant	UK	Wellcome Trust/Cancer Research UK	Wellcome Trust/Cancer Research UK
Tackling and investigating Escherichia coli Induced Diarrheal Diseases in Central and East Africa (ECOLI-CEA)	Below Threshold	Participant	CD	INSTITUT ONE HEALTH POUR L'AFRIQUE	INSTITUT ONE HEALTH POUR L'AFRIQUE
Tackling and investigating Escherichia coli Induced Diarrheal Diseases in Central and East Africa (ECOLI-CEA)	Below Threshold	Participant	CD	INRB	INSTITUT NATIONAL DE RECHERCHE
Next-gen cholera treatment for faster recovery, lower mortality and better outbreak control	Main list	Coordinator	ES	HB	Hunazine Biotech SL
Next-gen cholera treatment for faster recovery, lower mortality and better outbreak control	Main list	Participant	ZM	CIDRZ	Centre for Infectious Disease
Next-gen cholera treatment for faster recovery, lower mortality and better outbreak control	Main list	Participant	KE	ACE	AFRICA CLINICAL RESEARCH
Next-gen cholera treatment for faster recovery, lower mortality and better outbreak control	Main list	Participant	CM	CPC	CENTRE PASTEUR CAMEROON
Next-gen cholera treatment for faster recovery, lower mortality and better outbreak control	Main list	Participant	CD	UCB	UNIVERSITE CATHOLIQUE DE BUKAVU
Next-gen cholera treatment for faster recovery, lower mortality and better outbreak control	Main list	Participant	MW	CREAMS	Clinical Research Education and Management
Next-gen cholera treatment for faster recovery, lower mortality and better outbreak control	Main list	Participant	MZ	INS	Instituto Nacional de Saúde
Next-gen cholera treatment for faster recovery, lower mortality and better outbreak control	Main list	Participant	TZ	GSF-KCMC	THE GOOD SAMARITAN FOUNDATION
Next-gen cholera treatment for faster recovery, lower mortality and better outbreak control	Main list	Participant	BD	icddr,b	INTERNATIONAL CENTRE FOR DIARRHOEAL
Next-gen cholera treatment for faster recovery, lower mortality and better outbreak control	Main list	Participant	HU	Pannon	PANNONPHARMA Gyógyszergyártó
Next-gen cholera treatment for faster recovery, lower mortality and better outbreak control	Main list	Participant	NL	UMCG	ACADEMISCH ZIEKENHUIS CRONINGEN
OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children aged 1-2 years in Nigeria and Chad	Below Threshold	Coordinator	FR	UBx	UNIVERSITE DE BORDEAUX
OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children aged 1-2 years in Nigeria and Chad	Below Threshold	Participant - AF	FR	ADERA	ADERA SAS
OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children aged 1-2 years in Nigeria and Chad	Below Threshold	Participant	FR	INSERM	INSTITUT NATIONAL DE LA SANTE ET

OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children aged 1-3 years in Nigeria and Chad	Below Threshold	Participant	FR	IRD	INSTITUT DE RECHERCHE POUR LE
OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children aged 1-3 years in Nigeria and Chad	Below Threshold	Participant	FR	ALIMA	THE ALLIANCE FOR INTERNATIONAL
OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children aged 1-3 years in Nigeria and Chad	Below Threshold	Participant	CI	PACCI	ASSOCIATION PAC-CI
OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children aged 1-3 years in Nigeria and Chad	Below Threshold	Participant	FR	URN	UNIVERSITE DE ROUEN NORMANDIE
OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children aged 1-3 years in Nigeria and Chad	Below Threshold	Participant	UK	QUB	THE QUEEN'S UNIVERSITY OF BELFAST
OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children aged 1-3 years in Nigeria and Chad	Below Threshold	Participant	ML	INSP - Mali	Institut National de Santé Publique
OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children aged 1-3 years in Nigeria and Chad	Below Threshold	Participant	NG	UMTH	University of Maiduguri Teaching
OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children aged 1-3 years in Nigeria and Chad	Below Threshold	Participant	DE	HIGH	UNIVERSITÄTSKLINIKUM HEIDELBERG
OptiCrypto: a pair of individually randomized superiority trials to optimize treatment and prevention of cryptosporidium-associated diarrhea in children aged 1-3 years in Nigeria and Chad	Below Threshold	Participant	TD	HME	MOTHER AND CHILD TEACHING
SAFETY, EFFECTIVENESS AND COST-EFFECTIVENESS OF PROBIOTICS AS ADJUNCT PREVENTIVE THERAPY FOR CHILDHOOD DIARRHOEA AND ANTIMICROBIAL RESISTANCE IN AFRICA: A DOUBLE-BLINDED	Main list	Coordinator	NO	UiB	UNIVERSITETET I BERGEN
SAFETY, EFFECTIVENESS AND COST-EFFECTIVENESS OF PROBIOTICS AS ADJUNCT PREVENTIVE THERAPY FOR CHILDHOOD DIARRHOEA AND ANTIMICROBIAL RESISTANCE IN AFRICA: A DOUBLE-BLINDED	Main list	Participant	TZ	MUHAS	MUHIMBILI UNIVERSITY OF HEALTH AND
SAFETY, EFFECTIVENESS AND COST-EFFECTIVENESS OF PROBIOTICS AS ADJUNCT PREVENTIVE THERAPY FOR CHILDHOOD DIARRHOEA AND ANTIMICROBIAL RESISTANCE IN AFRICA: A DOUBLE-BLINDED	Main list	Participant	TZ	National Institute for Medical Research	National Institute for Medical Research
SAFETY, EFFECTIVENESS AND COST-EFFECTIVENESS OF PROBIOTICS AS ADJUNCT PREVENTIVE THERAPY FOR CHILDHOOD DIARRHOEA AND ANTIMICROBIAL RESISTANCE IN AFRICA: A DOUBLE-BLINDED	Main list	Participant	CI	PACCI	ASSOCIATION PAC-CI
SAFETY, EFFECTIVENESS AND COST-EFFECTIVENESS OF PROBIOTICS AS ADJUNCT PREVENTIVE THERAPY FOR CHILDHOOD DIARRHOEA AND ANTIMICROBIAL RESISTANCE IN AFRICA: A DOUBLE-BLINDED	Main list	Participant	MW	TRAINING & RESEARCH UNIT OF	TRAINING & RESEARCH UNIT OF
SAFETY, EFFECTIVENESS AND COST-EFFECTIVENESS OF PROBIOTICS AS ADJUNCT PREVENTIVE THERAPY FOR CHILDHOOD DIARRHOEA AND ANTIMICROBIAL RESISTANCE IN AFRICA: A DOUBLE-BLINDED	Main list	Participant - AP	TZ	Ministry of Community Development	Ministry of Community Development
Sustainable Approaches for Food-based Enhancement of Gut Health to tackle Childhood Diarrhoeal Diseases in the Context of Climate Change	Below Threshold	Coordinator	NL	STICHTING VU	STICHTING VU
Sustainable Approaches for Food-based Enhancement of Gut Health to tackle Childhood Diarrhoeal Diseases in the Context of Climate Change	Below Threshold	Participant	BE	ITM	INSTITUUT VOOR TROPISCHE
Sustainable Approaches for Food-based Enhancement of Gut Health to tackle Childhood Diarrhoeal Diseases in the Context of Climate Change	Below Threshold	Participant	FR	IRD	INSTITUT DE RECHERCHE POUR LE
Sustainable Approaches for Food-based Enhancement of Gut Health to tackle Childhood Diarrhoeal Diseases in the Context of Climate Change	Below Threshold	Participant	DE	HZI	HELMHOLTZ-ZENTRUM FÜR INFECTIOSE
Sustainable Approaches for Food-based Enhancement of Gut Health to tackle Childhood Diarrhoeal Diseases in the Context of Climate Change	Below Threshold	Participant	MZ	FM	FUNDAÇÃO MANHICA

Sustainable Approaches for Food-based Enhancement of Gut Health to tackle Childhood Diarrhoeal Diseases in the Context of Climate Change	Below Threshold	Participant	SN	UNIVERSITE CHEIKH ANTA DIOP DE	UNIVERSITE CHEIKH ANTA DIOP
Sustainable Approaches for Food-based Enhancement of Gut Health to tackle Childhood Diarrhoeal Diseases in the Context of Climate Change	Below Threshold	Participant	BF	CNRST/IRSS-DRCO/Clinical Research Unit	Clinical Research Unit of Nanoro
Sustainable Approaches for Food-based Enhancement of Gut Health to tackle Childhood Diarrhoeal Diseases in the Context of Climate Change	Below Threshold	Participant	MW	KAMUZU UNIVERSITY OF HEALTH	KAMUZU UNIVERSITY OF HEALTH
Integrated Public Health and Climate Resilience Strategies for Tackling Antibiotic-Resistant Shigella and Reducing Diarrhea in Sub-Sahara Africa	Below Threshold	Coordinator	ZA	RHODES UNIVERSITY	RHODES UNIVERSITY
Integrated Public Health and Climate Resilience Strategies for Tackling Antibiotic-Resistant Shigella and Reducing Diarrhea in Sub-Sahara Africa	Below Threshold	Participant	ZA	Synergy Biomed Research	Synergy Biomed Research Institute (Pty) Ltd
Integrated Public Health and Climate Resilience Strategies for Tackling Antibiotic-Resistant Shigella and Reducing Diarrhea in Sub-Sahara Africa	Below Threshold	Participant	KE	APHRC	AFRICAN POPULATION & HEALTH
Integrated Public Health and Climate Resilience Strategies for Tackling Antibiotic-Resistant Shigella and Reducing Diarrhea in Sub-Sahara Africa	Below Threshold	Participant	SN	RESEAU AFRICAINE DE RECHERCHE	RESEAU AFRICAINE DE RECHERCHE
Integrated Public Health and Climate Resilience Strategies for Tackling Antibiotic-Resistant Shigella and Reducing Diarrhea in Sub-Sahara Africa	Below Threshold	Participant	DE	USAAR	UNIVERSITAT DES SAARLANDES
Integrated Public Health and Climate Resilience Strategies for Tackling Antibiotic-Resistant Shigella and Reducing Diarrhea in Sub-Sahara Africa	Below Threshold	Participant	CH	SWISS TPH	SCHWEIZERISCHE TROPEN UND PUBLIC
Integrated Public Health and Climate Resilience Strategies for Tackling Antibiotic-Resistant Shigella and Reducing Diarrhea in Sub-Sahara Africa	Below Threshold	Participant	CI	UNIVERSITE FELIX HOUPHOUET	UNIVERSITE FELIX HOUPHOUET
Integrated Public Health and Climate Resilience Strategies for Tackling Antibiotic-Resistant Shigella and Reducing Diarrhea in Sub-Sahara Africa	Below Threshold	Participant	ZA	UCT	UNIVERSITY OF CAPE TOWN
TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea and malnutrition	Main list	Coordinator	NL	AUMC	STICHTING AMSTERDAM UMC
TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea and malnutrition	Main list	Participant - AF	NL	AIGHD	STICHTING AMSTERDAM INSTITUTE FOR
TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea and malnutrition	Main list	Participant	KE	KEMRI	KENYA MEDICAL RESEARCH
TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea and malnutrition	Main list	Participant	TZ	HGHRI	Haydom Lutheran Hospital
TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea and malnutrition	Main list	Participant	FR	3OC	THREE O'CLOCK
TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea and malnutrition	Main list	Participant	TZ	NIMR	NATIONAL INSTITUTE FOR MEDICAL
TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea and malnutrition	Main list	Participant	TZ	TMA	TANZANIA METEOROLOGICAL
TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea and malnutrition	Main list	Participant - AP	US	UVA	UNIVERSITY OF VIRGINIA
TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea and malnutrition	Main list	Participant - AP	US	Emory	EMORY UNIVERSITY NON PROFIT

TARGET: Targeted antibiotic therapy for high-risk children with watery diarrhoea and malnutrition	Main list	Participant - AP	US	UW	UNIVERSITY OF WASHINGTON
---	-----------	------------------	----	----	--------------------------

Legal type	Is SME?	Total costs	Requested EU contribution
Private for Profit	N	406.250,00 €	406.250,00 €
Private for Profit	N	1.169.837,50 €	1.169.837,50 €
Higher or Secondary Education	N	130.000,00 €	130.000,00 €
Higher or Secondary Education	N	110.000,00 €	110.000,00 €
Higher or Secondary Education	N	0,00 €	0,00 €
Public Body	N	91.700,00 €	91.700,00 €
Research Organisation	N	85.275,00 €	85.275,00 €
Higher or Secondary Education	N	6.937,50 €	6.937,50 €
Higher or Secondary Education	N	466.945,00 €	466.945,00 €
Higher or Secondary Education	N	605.772,50 €	605.772,50 €
Higher or Secondary Education	N	299.445,00 €	299.445,00 €
Other	N	469.465,00 €	469.465,00 €
Higher or Secondary Education	N	134.843,75 €	134.843,75 €
Research Organisation	N	82.692,50 €	82.692,50 €
Higher or Secondary Education	N	367.292,50 €	367.292,50 €
Higher or Secondary Education	N	72.758,75 €	72.758,75 €
Private for Profit	Y	738.475,75 €	738.475,75 €

Higher or Secondary Education	N	542.406,25 €	542.406,25 €
Private for Profit	Y	378.812,50 €	378.812,50 €
Higher or Secondary Education	N	721.510,25 €	671.510,25 €
Private for Profit	Y	442.498,75 €	429.998,75 €
Higher or Secondary Education	N	616.646,25 €	429.146,25 €
Higher or Secondary Education	N	426.250,00 €	370.000,00 €
Private for Profit	Y	81.250,00 €	0,00 €
Private for Profit	Y	276.250,00 €	276.250,00 €
Higher or Secondary Education	N	315.435,00 €	315.435,00 €
Research Organisation	N	679.222,25 €	679.222,25 €
Higher or Secondary Education	N	263.188,75 €	263.188,75 €
Research Organisation	N	209.531,25 €	209.531,25 €
Private for Profit	Y	248.281,25 €	248.281,25 €
Higher or Secondary Education	N	245.767,50 €	245.767,50 €
Research Organisation	N	453.000,50 €	453.000,50 €
Research Organisation	N	0,00 €	0,00 €
Higher or Secondary Education	N	703.260,00 €	703.260,00 €
Other	N	800.180,00 €	800.180,00 €
Research Organisation	N	596.560,00 €	596.560,00 €
Higher or Secondary Education	N	923.901,25 €	923.901,25 €

Other	N	278.125,00 €	278.125,00 €
Private for Profit	N	132.340,00 €	132.340,00 €
Private for Profit	N	272.525,00 €	272.525,00 €
Research Organisation	N	669.287,50 €	669.287,50 €
Other	N	464.651,25 €	464.651,25 €
Higher or Secondary Education	N	1.003.088,75 €	1.003.088,75 €
Research Organisation	N	686.917,25 €	686.917,25 €
Other	N	280.983,75 €	280.983,75 €
Research Organisation	N	212.548,25 €	212.548,25 €
Private for Profit	Y	116.461,25 €	116.461,25 €
Public Body	N	0,00 €	0,00 €
Private for Profit	N	0,00 €	0,00 €
Other	N	0,00 €	0,00 €
Other	Y	830.500,00 €	780.500,00 €
Higher or Secondary Education	N	516.801,25 €	516.801,00 €
Research Organisation	N	436.482,50 €	436.482,50 €
Higher or Secondary Education	N	443.865,00 €	443.865,00 €
Higher or Secondary Education	N	268.103,75 €	249.505,00 €
Higher or Secondary Education	N	387.781,25 €	387.781,25 €
Private for Profit	Y	799.750,00 €	799.750,00 €

Research Organisation	N	506.243,75 €	506.243,75 €
Private for Profit	Y	172.662,50 €	172.662,50 €
Higher or Secondary Education	N	312.920,50 €	312.920,50 €
Higher or Secondary Education	N	342.470,00 €	342.470,00 €
Research Organisation	N	195.858,75 €	195.858,75 €
Higher or Secondary Education	N	0,00 €	0,00 €
Public Body	N	863.892,50 €	863.892,50 €
Research Organisation	N	1.299.980,00 €	1.299.980,00 €
Research Organisation	N	1.000.000,00 €	1.000.000,00 €
Research Organisation	N	850.450,00 €	850.450,00 €
Research Organisation	N	158.325,00 €	158.325,00 €
Research Organisation	N	999.625,00 €	999.625,00 €
Higher or Secondary Education	N	944.750,00 €	944.750,00 €
Higher or Secondary Education	N	890.068,75 €	890.068,75 €
Research Organisation	N	202.528,75 €	202.528,75 €
Higher or Secondary Education	N	986.192,50 €	986.192,50 €
Higher or Secondary Education	N	805.256,25 €	805.256,25 €
Research Organisation	N	118.381,25 €	118.381,25 €
Private for Profit	N	144.975,00 €	144.975,00 €
Other	Y	93.750,00 €	93.750,00 €

Higher or Secondary Education	N	139.437,50 €	139.437,50 €
Research Organisation	N	513.336,25 €	513.336,25 €
Higher or Secondary Education	N	270.000,00 €	270.000,00 €
Higher or Secondary Education	N	466.250,00 €	466.250,00 €
Private for Profit	Y	796.250,00 €	796.250,00 €
Higher or Secondary Education	N	337.000,00 €	337.000,00 €
Higher or Secondary Education	N	116.500,00 €	116.500,00 €
Higher or Secondary Education	N	738.765,00 €	738.765,00 €
Private for Profit	Y	759.966,25 €	759.966,25 €
Higher or Secondary Education	N	329.862,50 €	329.862,50 €
Research Organisation	N	345.000,00 €	345.000,00 €
Research Organisation	N	465.360,00 €	465.360,00 €
Higher or Secondary Education	N	114.960,00 €	114.960,00 €
Higher or Secondary Education	N	429.020,00 €	429.020,00 €
Private for Profit	Y	387.250,00 €	387.250,00 €
Higher or Secondary Education	N	257.872,50 €	257.872,50 €
Higher or Secondary Education	N	223.525,00 €	223.525,00 €
Private for Profit	Y	490.625,00 €	490.625,00 €
Research Organisation	N	369.996,25 €	369.996,25 €
Higher or Secondary Education	N	414.250,00 €	414.250,00 €

Higher or Secondary Education	N	246.453,75 €	246.453,75 €
Private for Profit	Y	582.153,75 €	582.153,75 €
Research Organisation	N	110.875,00 €	110.875,00 €
Higher or Secondary Education	N	97.750,00 €	97.750,00 €
Higher or Secondary Education	N	105.750,00 €	105.750,00 €
Research Organisation	N	59.500,00 €	59.500,00 €
Private for Profit	Y	195.000,00 €	195.000,00 €
Private for Profit	N	101.358,75 €	101.358,75 €
Private for Profit	Y	100.500,00 €	100.500,00 €
Higher or Secondary Education	N	0,00 €	0,00 €
Research Organisation	N	0,00 €	0,00 €
Research Organisation	N	75.500,00 €	75.500,00 €
Higher or Secondary Education	N	505.526,25 €	505.526,25 €
Research Organisation	N	138.450,00 €	138.450,00 €
Higher or Secondary Education	N	101.567,50 €	101.567,50 €
Private for Profit	N	282.825,00 €	282.825,00 €
Higher or Secondary Education	N	164.125,00 €	164.125,00 €
Research Organisation	N	185.937,50 €	185.937,50 €
Higher or Secondary Education	N	166.825,00 €	166.825,00 €
Private for Profit	Y	215.860,00 €	215.860,00 €

Research Organisation	N	97.912,50 €	97.912,50 €
Research Organisation	Y	133.387,50 €	133.387,50 €
Research Organisation	N	169.351,25 €	169.351,25 €
Private for Profit	Y	199.097,50 €	199.097,50 €
Public Body	N	0,00 €	0,00 €
Higher or Secondary Education	N	912.659,25 €	912.659,25 €
Higher or Secondary Education	N	622.993,75 €	622.993,75 €
Research Organisation	N	372.592,50 €	372.592,50 €
Private for Profit	N	191.380,00 €	191.380,00 €
Research Organisation	N	148.116,25 €	148.116,25 €
Research Organisation	N	359.848,75 €	359.848,75 €
Higher or Secondary Education	N	803.126,25 €	803.126,25 €
Higher or Secondary Education	N	885.276,25 €	885.276,25 €
Higher or Secondary Education	N	198.406,25 €	198.406,25 €
Higher or Secondary Education	N	953.708,75 €	953.708,75 €
Research Organisation	N	1.088.410,00 €	1.088.410,00 €
Higher or Secondary Education	N	238.793,75 €	238.793,75 €
Higher or Secondary Education	N	6.851,25 €	6.851,25 €
Higher or Secondary Education	N	9.736,25 €	9.736,25 €
Research Organisation	N	903.996,25 €	886.916,25 €

Higher or Secondary Education	N	701.178,75 €	701.178,75 €
Other	N	764.163,75 €	764.163,75 €
Higher or Secondary Education	N	472.946,25 €	472.945,44 €
Private for Profit	N	1.208.381,25 €	1.063.376,00 €
Higher or Secondary Education	N	795.498,75 €	763.678,56 €
Research Organisation	N	261.250,00 €	250.625,00 €
Research Organisation	N	768.557,50 €	768.557,50 €
Higher or Secondary Education	N	569.455,00 €	569.455,00 €
Higher or Secondary Education	N	711.797,50 €	711.797,50 €
Research Organisation	N	0,00 €	0,00 €
Research Organisation	N	1.128.585,00 €	1.128.585,00 €
Research Organisation	N	421.975,00 €	421.975,00 €
Higher or Secondary Education	N	510.363,75 €	510.363,00 €
Other	N	563.437,50 €	563.437,50 €
Research Organisation	N	141.151,25 €	141.151,25 €
Private for Profit	Y	278.998,75 €	278.998,75 €
Research Organisation	N	389.740,00 €	389.740,00 €
Research Organisation	N	110.991,25 €	110.991,25 €
Private for Profit	N	264.875,00 €	264.875,00 €
Research Organisation	Y	253.958,75 €	253.958,75 €

Higher or Secondary Education	N	245.828,75 €	245.828,75 €
Research Organisation	N	373.750,00 €	373.750,00 €
Private for Profit	N	165.426,25 €	165.426,25 €
Higher or Secondary Education	N	142.950,00 €	142.950,00 €
Private for Profit	Y	265.250,00 €	265.250,00 €
Research Organisation	N	281.371,25 €	281.371,25 €
Public Body	N	328.812,50 €	328.812,50 €
Research Organisation	N	341.750,00 €	341.750,00 €
Private for Profit	Y	464.125,00 €	464.125,00 €
Higher or Secondary Education	N	341.625,00 €	341.625,00 €
Higher or Secondary Education	N	1.711.560,25 €	1.711.560,25 €
Higher or Secondary Education	N	2.068.586,25 €	2.068.586,25 €
Higher or Secondary Education	N	354.181,25 €	354.181,25 €
Higher or Secondary Education	N	548.683,75 €	548.683,75 €
Other	N	465.015,00 €	465.015,00 €
Other	N	94.322,50 €	94.322,50 €
Private for Profit	Y	57.026,25 €	57.026,25 €
Higher or Secondary Education	N	1.121.375,00 €	1.121.375,00 €
Higher or Secondary Education	N	1.367.258,75 €	1.367.258,75 €
Other	Y	1.140.386,25 €	1.140.386,25 €

Other	N	379.504,50 €	379.504,50 €
Higher or Secondary Education	N	279.948,75 €	279.948,75 €
Private for Profit	Y	520.312,50 €	520.312,50 €
Research Organisation	N	599.178,75 €	599.178,75 €
Higher or Secondary Education	N	718.783,75 €	718.783,75 €
Higher or Secondary Education	N	2.008.587,50 €	2.008.587,50 €
Higher or Secondary Education	N	73.687,50 €	73.687,50 €
Higher or Secondary Education	N	383.417,50 €	383.417,50 €
Higher or Secondary Education	N	335.062,50 €	335.062,50 €
Higher or Secondary Education	N	271.100,00 €	271.100,00 €
Research Organisation	N	110.913,75 €	110.913,75 €
Private for Profit	N	110.913,75 €	110.913,75 €
Higher or Secondary Education	N	174.625,00 €	174.625,00 €
Research Organisation	N	113.567,50 €	113.567,50 €
Research Organisation	N	174.625,00 €	174.625,00 €
Private for Profit	N	55.587,50 €	55.587,50 €
Private for Profit	N	169.948,75 €	169.948,75 €
Other	N	332.437,50 €	332.437,00 €
Higher or Secondary Education	N	1.256.750,00 €	1.256.750,00 €
Other	N	579.618,75 €	579.618,00 €

Research Organisation	N	453.031,25 €	453.031,00 €
Higher or Secondary Education	N	640.875,00 €	640.875,00 €
Research Organisation	N	819.363,75 €	819.363,00 €
Other	N	0,00 €	0,00 €
Higher or Secondary Education	N	603.743,75 €	603.743,00 €
Research Organisation	N	845.125,00 €	845.125,00 €
Private for Profit	Y	2.569.812,50 €	2.569.812,50 €
Other	N	332.591,25 €	332.591,25 €
Private for Profit	N	652.083,75 €	652.083,75 €
Research Organisation	N	287.271,25 €	287.271,25 €
Higher or Secondary Education	N	186.480,00 €	186.480,00 €
Research Organisation	N	276.916,25 €	276.916,25 €
Research Organisation	N	184.330,00 €	184.330,00 €
Other	N	266.887,50 €	266.887,50 €
Research Organisation	N	240.000,00 €	240.000,00 €
Private for Profit	Y	300.640,00 €	300.640,00 €
Higher or Secondary Education	N	331.250,00 €	331.250,00 €
Higher or Secondary Education	N	318.480,00 €	318.480,00 €
Private for Profit	N	120.000,00 €	120.000,00 €
Research Organisation	N	368.843,75 €	368.843,75 €

Research Organisation	N	277.145,00 €	277.145,00 €
Other	N	2.573.323,75 €	2.573.323,75 €
Research Organisation	N	405.682,50 €	405.682,50 €
Higher or Secondary Education	N	596.470,00 €	596.470,00 €
Higher or Secondary Education	N	84.985,00 €	84.985,00 €
Research Organisation	N	253.918,75 €	253.918,75 €
Higher or Secondary Education	N	166.952,50 €	166.952,50 €
Higher or Secondary Education	N	262.991,25 €	262.991,25 €
Higher or Secondary Education	N	158.931,25 €	158.931,25 €
Higher or Secondary Education	N	3.443.455,00 €	2.909.453,75 €
Higher or Secondary Education	N	755.998,75 €	755.998,75 €
Research Organisation	N	47.007,50 €	47.007,50 €
Research Organisation	N	791.006,25 €	791.006,25 €
Research Organisation	N	796.533,75 €	796.533,75 €
Public Body	N	0,00 €	0,00 €
Higher or Secondary Education	N	931.435,00 €	931.435,00 €
Higher or Secondary Education	N	594.285,00 €	594.285,00 €
Research Organisation	N	490.000,00 €	490.000,00 €
Research Organisation	N	560.065,00 €	560.065,00 €
Research Organisation	N	710.927,50 €	710.927,50 €

Higher or Secondary Education	N	634.750,75 €	634.750,75 €
Research Organisation	N	720.693,75 €	720.693,75 €
Higher or Secondary Education	N	657.795,00 €	657.795,00 €
Higher or Secondary Education	N	1.025.375,00 €	1.025.375,00 €
Research Organisation	Y	419.832,50 €	419.832,50 €
Research Organisation	N	553.125,00 €	553.125,00 €
Other	N	724.375,00 €	724.375,00 €
Higher or Secondary Education	N	370.625,00 €	370.625,00 €
Research Organisation	N	1.189.725,00 €	1.189.725,00 €
Higher or Secondary Education	N	530.782,50 €	530.782,50 €
Higher or Secondary Education	N	464.940,00 €	464.940,00 €
Research Organisation	N	997.777,50 €	997.777,50 €
Research Organisation	N	679.707,50 €	679.707,50 €
Research Organisation	N	1.931.235,00 €	1.931.235,00 €
Other	N	1.793.302,50 €	1.793.302,50 €
Private for Profit	Y	278.125,00 €	278.125,00 €
Research Organisation	N	37.943,75 €	37.943,75 €
Public Body	N	81.875,00 €	81.875,00 €
Higher or Secondary Education	N	0,00 €	0,00 €
Higher or Secondary Education	N	0,00 €	0,00 €

Higher or Secondary Education	N	0,00 €	0,00 €
-------------------------------------	---	--------	--------

ANNEX 7 Table 8: Country participation and share of requested EU contribution in evaluated and retained for funding proposals

Country Group	Country	N. Participations in evaluated proposals	N. Participations in retained for funding proposals	%	Requested EU contribution in evaluated proposals	Requested EU contribution in retained for funding proposals	%
Associated Countries	Georgia	1	1	100,00 %	191.380,00 €	191.380,00 €	100,00 %
Associated Countries	Norway	1	1	100,00 %	2.909.453,75 €	2.909.453,75 €	100,00 %
Associated Countries	United Kingdom	31	7	22,58 %	14.102.550,19 €	3.173.283,25 €	22,50 %
Associated Countries		33	9	27,27 %	17.203.383,94 €	6.274.117,00 €	36,47 %
EU Member States	Belgium	8	0	0,00 %	3.854.517,50 €	0,00 €	0,00 %
EU Member States	Czechia	1	0	0,00 %	94.322,50 €	0,00 €	0,00 %
EU Member States	Denmark	2	0	0,00 %	1.251.943,75 €	0,00 €	0,00 %
EU Member States	France	18	3	16,67 %	7.699.087,25 €	1.026.933,75 €	13,34 %
EU Member States	Germany	16	4	25,00 %	7.104.762,25 €	2.277.338,00 €	32,05 %
EU Member States	Hungary	1	1	100,00 %	300.640,00 €	300.640,00 €	100,00 %
EU Member States	Italy	5	1	20,00 %	1.539.477,00 €	279.948,75 €	18,18 %
EU Member States	Netherlands	11	7	63,64 %	5.056.750,00 €	3.080.137,50 €	60,91 %
EU Member States	Portugal	1	0	0,00 %	890.068,75 €	0,00 €	0,00 %
EU Member States	Spain	13	3	23,08 %	7.551.617,50 €	3.201.116,25 €	42,39 %
EU Member States	Sweden	1	0	0,00 %	249.505,00 €	0,00 €	0,00 %
EU Member States		77	19	24,68 %	35.592.691,50 €	10.166.114,25 €	28,56 %

Third countries	Bangladesh	1	1	100,00 %	240.000,00 €	240.000,00 €	100,00 %
Third countries	Benin	2	0	0,00 %	811.215,00 €	0,00 €	0,00 %
Third countries	Burkina Faso	4	0	0,00 %	2.660.347,50 €	0,00 €	0,00 %
Third countries	Burundi	1	0	0,00 %	640.875,00 €	0,00 €	0,00 %
Third countries	Cameroon	3	1	33,33 %	1.296.046,25 €	287.271,25 €	22,17 %
Third countries	Chad	1	0	0,00 %	158.931,25 €	0,00 €	0,00 %
Third countries	Congo	1	0	0,00 %	579.618,00 €	0,00 €	0,00 %
Third countries	Congo (Democratic Republic of)	7	1	14,29 %	3.861.479,25 €	186.480,00 €	4,83 %
Third countries	Cote d'Ivoire	3	1	33,33 %	1.727.471,25 €	791.006,25 €	45,79 %
Third countries	Egypt	1	0	0,00 %	105.750,00 €	0,00 €	0,00 %
Third countries	Ethiopia	4	1	25,00 %	439.004,50 €	379.504,50 €	86,45 %
Third countries	Gabon	1	0	0,00 %	185.937,50 €	0,00 €	0,00 %
Third countries	Gambia	1	0	0,00 %	436.482,50 €	0,00 €	0,00 %
Third countries	Ghana	7	0	0,00 %	1.888.082,50 €	0,00 €	0,00 %
Third countries	Guinea	2	0	0,00 %	669.287,50 €	0,00 €	0,00 %
Third countries	Guinea-Bissau	1	0	0,00 %	596.560,00 €	0,00 €	0,00 %
Third countries	India	1	0	0,00 %	0,00 €	0,00 €	0,00 %
Third countries	Kenya	11	2	18,18 %	4.843.994,25 €	2.583.318,75 €	53,33 %
Third countries	Malawi	6	3	50,00 %	3.404.433,50 €	1.615.856,25 €	47,46 %
Third countries	Mali	5	0	0,00 %	3.535.957,25 €	0,00 €	0,00 %

Third countries	Mauritius	1	0	0,00 %	679.222,25 €	0,00 €	0,00 %
Third countries	Mozambique	7	2	28,57 %	3.298.077,50 €	574.070,00 €	17,41 %
Third countries	Namibia	1	1	100,00 %	370.000,00 €	370.000,00 €	100,00 %
Third countries	Nigeria	9	0	0,00 %	2.286.741,25 €	0,00 €	0,00 %
Third countries	Senegal	4	0	0,00 %	1.634.250,75 €	0,00 €	0,00 %
Third countries	South Africa	22	8	36,36 %	12.873.216,25 €	5.556.726,50 €	43,17 %
Third countries	Switzerland	5	1	20,00 %	2.056.366,25 €	372.592,50 €	18,12 %
Third countries	Tanzania (United Republic of)	14	9	64,29 %	5.697.083,00 €	3.403.165,00 €	59,74 %
Third countries	Uganda	11	4	36,36 %	6.734.239,81 €	2.689.218,75 €	39,93 %
Third countries	United States	4	3	75,00 %	0,00 €	0,00 €	0,00 %
Third countries	Zambia	5	3	60,00 %	2.148.091,25 €	1.354.627,50 €	63,06 %
Third countries	Zimbabwe	2	1	50,00 %	333.525,00 €	223.525,00 €	67,02 %
Third countries		148	42	28,38 %	66.192.286,31 €	20.627.362,25 €	31,16 %
GRAND TOTAL		258	70	27,13 %	118.988.361,75 €	37.067.593,50 €	31,15 %